64 results on '"Nuria Espinosa"'
Search Results
2. Long-term effectiveness, safety, and tolerability of doravirine in antiretroviral-experienced people with HIV in real life
- Author
-
Marta Mejías-Trueba, Alicia Gutierrez-Valencia, Silvia Llaves-Flores, Cristina Roca-Oporto, Marta Herrero, César Sotomayor de la Piedra, Luis F. Lopez-Cortes, and Nuria Espinosa
- Subjects
HIV cure ,ARV ,viral supression ,treatment ,Microbiology ,QR1-502 - Abstract
ABSTRACT Real-life data on doravirine (DOR) in different drug combinations are limited. We evaluated the effectiveness of DOR plus two nucleos(t)ide reverse transcriptase inhibitors (NRTI), mainly abacavir/lamivudine, and dual therapies in people with HIV (PWH), mostly virologically suppressed. Ambispective observational study that enrolled adults PWH who initiated a DOR-based regimen from September 2020 to February 2022 at a referral center in Spain. Participants were grouped as follows: A, received DOR plus two NRTI; B, dual therapy (DT) with DOR plus dolutegravir (DTG) or darunavir/cobicistat (DRVc); C, DOR plus ≥two antiretroviral drugs. The primary endpoints were treatment effectiveness at week 48 by intention-to-treat (ITT) and per-protocol analysis (OT). A cohort of 187 participants, 91% virologically suppressed, were analyzed after a median follow-up of 112 weeks (80–136). Group A received DOR plus abacavir/lamivudine (ABV/3TC) (n = 109) or tenofovir/emtricitabine (TFV/3TC) (n = 45). At week 48, the effectiveness of DOR plus ABV/3TC by ITT was 90.8% (CI95, 88.0–93.6), better than with TFV/FTC [73.3% (66.7–79.9); P = 0.003]. Only one virologic failure was observed. Mild adverse effects were the cause of treatment discontinuation in 7.8%, followed by switching to a single-tablet regimen. In group B, the effectiveness by ITT was 92.9% (CI95, 88.0–97.8) at week 48. No adverse effects or virologic failure were registered in this group. DOR plus two NRTI or DT have long-term effectiveness and safety as a switching option for PWH, mostly virologically suppressed. The DOR plus ABV/3TC combination has shown even better effectiveness than TFV/FTC.IMPORTANCEDOR-based regimens have shown long-term effectiveness and safety in PWH, mostly virologically suppressed. The combination of DOR plus ABV/3TC has shown even better safety and effectiveness than TFV/FTC. DOR plus two NRTI offers cost benefits compared to other regimens.
- Published
- 2024
- Full Text
- View/download PDF
3. Rat hepatitis E virus (Rocahepevirus ratti) in people living with HIV
- Author
-
María Casares-Jimenez, Antonio Rivero-Juarez, Pedro Lopez-Lopez, María Luisa Montes, Roser Navarro-Soler, Joaquín Peraire, Nuria Espinosa, María Remedios Alemán-Valls, Tránsito Garcia-Garcia, Javier Caballero-Gomez, Diana Corona-Mata, Ignacio Perez-Valero, Rainer G. Ulrich, and Antonio Rivero
- Subjects
Hepatitis E ,rat hepatitis E virus ,acute hepatitis ,HIV ,Zoonoses ,public health ,Infectious and parasitic diseases ,RC109-216 ,Microbiology ,QR1-502 - Abstract
ABSTRACTRat hepatitis E virus (ratHEV; species Rocahepevirus ratti) is considered a newly emerging cause of acute hepatitis of zoonotic origin. ratHEV infection of people living with HIV (PLWH) might portend a worse, as with hepatitis E virus (HEV; species Paslahepevirus balayani), and consequently this group may constitute a high-risk population. We aimed to evaluate the prevalence of ratHEV by measuring viral RNA and specific IgG antibodies in a large Spanish cohort of PLWH. Multicentre study conducted in Spain evaluating PLWHIV included in the Spanish AIDS Research Network (CoRIS). Patients were evaluated for ratHEV infection using PCR at baseline and anti-ratHEV IgG by dot blot analysis to evaluate exposure to ratHEV strains. Patients with detectable ratHEV RNA were followed-up to evaluate persistence of viremia and IgG seroconversion. Eight-hundred and forty-two individuals were tested. A total of 9 individuals showed specific IgG antibodies against ratHEV, supposing a prevalence of 1.1 (95% CI; 0.5%−2.1%). Of these, only one was reactive to HEV IgG antibodies by ELISA. One sample was positive for ratHEV RNA (prevalence of infection: 0.1%; 95% CI: 0.08%−0.7%). The case was a man who had sex with men exhibiting a slightly increased alanine transaminase level (49 IU/L) as only biochemical alteration. In the follow-up, the patients showed undetectable ratHEV RNA and seroconversion to specific ratHEV IgG antibodies. Our study shows that ratHEV is geographical broadly distributed in Spain, representing a potential zoonotic threat.
- Published
- 2024
- Full Text
- View/download PDF
4. Long-term effects on immunological, inflammatory markers, and HIV-1 reservoir after switching to a two-drug versus maintaining a three-drug regimen based on integrase inhibitors
- Author
-
Abraham Saborido-Alconchel, Ana Serna-Gallego, María Trujillo-Rodriguez, Esperanza Muñoz-Muela, Ana I. Álvarez-Ríos, Carmen Lozano, Silvia Llaves-Flores, Nuria Espinosa, Cristina Roca-Oporto, Marta Herrero, Cesar Sotomayor, Alicia Gutierrez-Valencia, and Luis F. Lopez-Cortes
- Subjects
HIV-1 infection ,HIV-1 treatment ,long-term ,inflammation ,antiretroviral therapy ,dual therapy ,Immunologic diseases. Allergy ,RC581-607 - Abstract
ObjectiveTo compare the long-term effects on immune parameters, inflammation, and HIV-1 reservoir after switching to a two-drug (2DR) versus maintaining an integrase inhibitor (InSTI)-based three-drug regimen (3DR).MethodsCross-sectional study in which HIV-1 treatment-naïve people started and maintained an InSTI-based 3DR or, at different times, switched to 2DR (dolutegravir or darunavir/cobicistat + lamivudine). CD4+ and CD8+ T-cell activation and exhaustion, plasma concentrations of hs-CRP, D-dimer, P-selectin, IL-1β, IL-6, TNF-α, IFN-γ, IP-10, sTNFR-I/II, MIP-1α/β, I-FABP, LBP, sCD14, sCD163, MCP-1, and cellular-associated HIV-1-DNA and -RNA were quantified by flow cytometry, different immunoassays, and droplet digital PCR, respectively. The U de Mann-Whitney test evaluated differences between 3DR and 2DR. Immune recovery was evaluated using a general linear model for repeated measures adjusted for different co-variables.ResultsFifty participants per group were included. The median time on 3DR was 82 months for the 3DR group and 30 months for the 2DR group, after which it switched to 2DR for a median of 57 months. We did not find differences between both groups in any of the parameters analyzed. Specifically, some values in 3DR and 2DR were hs-CRP, 0.92 mg/L (0.45–2.23) vs. 1.23 (0.61–2.38); D-dimer, 190.0 µg/L (150.0–370.0) vs. 190.0 (150.0–397.5); IL-6, 2.8 pg/mL (1.3–5.3) vs. 3.2 (2.1–4.7); sCD14, 4.5 ng/mL (3.3–6.2) vs. 5.0 (3.6–6.1), respectively, all p ≥ 0.399.ConclusionIn the long term, switching to 2DR does not negatively affect immunologic parameters, inflammatory markers, or HIV-1 reservoir.Clinical trial registrationidentifier NCT04076423.
- Published
- 2024
- Full Text
- View/download PDF
5. Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS eventsResearch in context
- Author
-
Javier Martínez-Sanz, Jorge Díaz-Álvarez, Marta Rosas, Raquel Ron, José Antonio Iribarren, Enrique Bernal, Félix Gutiérrez, Andrés Ruiz Sancho, Noemi Cabello, Julián Olalla, Santiago Moreno, Sergio Serrano-Villar, Inma Jarrín, David Dalmau, M. Luisa Navarro, M. Isabel González, Federico Garcia, Eva Poveda, Jose Antonio Iribarren, Rafael Rubio, Francesc Vidal, Juan Berenguer, Juan González, M. Ángeles Muñoz-Fernández, Inmaculada Jarrín, Cristina Moreno, Marta Rava, Rebeca Izquierdo, Elba Mauleón, Joaquín Portilla, Irene Portilla, Esperanza Merino, Gema García, Iván Agea, José Sánchez-Payá, Juan Carlos Rodríguez, Livia Giner, Sergio Reus, Vicente Boix, Diego Torrus, Verónica Pérez, Julia Portilla, Juan Luís Gómez, Jehovana Hernández, Ana López Lirola, Dácil García, Felicitas Díaz-Flores, M. Mar Alonso, Ricardo Pelazas, M. Remedios Alemán, Víctor Asensi, María Eugenia Rivas Carmenado, Tomás Suarez-Zarracina, Federico Pulido, Otilia Bisbal, M. Asunción Hernando, David Rial, María de Lagarde, Octavio Arce, Adriana Pinto, Laura Bermejo, Mireia Santacreu, Roser Navarro, Candela Gonzalez, M. José Aramburu, Xabier Camino, Miguel Ángel von Wichmann, Miguel Ángel Goenaga, M. Jesús Bustinduy, Harkaitz Azkune, Maialen Ibarguren, Xabier Kortajarena, Ignacio Álvarez-Rodriguez, Leire Gil, Lourdes Martínez, Catalina Robledano, Mar Masiá, Sergio Padilla, Araceli Adsuar, Rafael Pascual, Marta Fernández, Antonio Galiana, José Alberto García, Xavier Barber, Vanessa Agullo, Javier Garcia Abellán, Reyes Pascual, Guillermo Telenti, Lucia Guillén, Ángela Botella, Roberto Muga, Arantza Sanvisens, Daniel Fuster, Isabel Gutierrez, Juan Carlos López, Margarita Ramírez, Belén Padilla, Paloma Gijón, Teresa Aldamiz-Echevarría, Francisco Tejerina, Cristina Diez, Leire Pérez, Chiara Fanciulli, Saray Corral, Anna Martí, Joaquín Peraire, Consuelo Viladés, Montserrat Vargas, Montserrat Olona, Anna Rull, Verónica Alba, Elena Yeregui, Jenifer Masip, Graciano García-Pardo, Frederic Gómez Bertomeu, Sonia Espineira, Marta Montero, Sandra Cuéllar, Marino Blanes, María Tasias, Eva Calabuig, Miguel Salavert, Juan Fernández, Inmaculada Segarra, Juan González-García, Ana Delgado, Francisco Arnalich, José Ramón Arribas, Jose Ignacio Bernardino, Juan Miguel Castro, Luis Escosa, Pedro Herranz, Victor Hontañón, Silvia García-Bujalance, Milagros García, Alicia González-Baeza, M. Luz Martín-Carbonero, Mario Mayoral, M. Jose Mellado, Rafael Esteban, Rocío Montejano, M. Luisa Montes, Victoria Moreno, Ignacio Pérez-Valero, Berta Rodés, Guadalupe Rúa, Talía Sainz, Elena Sendagorta, Eulalia Valencia, Carmen Busca, Joanna Cano, Julen Cardiñanos, Rosa de Miguel, Jose Ramón Blanco, Laura Pérez-Martínez, José Antonio Oteo, Valvanera Ibarra, Luis Metola, Mercedes Sanz, Piedad Arazo, Gloria Sampériz, Marina Martinez, Angels Jaén, Montse Sanmartí, Mireia Cairó, Javier Martinez-Lacasa, Pablo Velli, Roser Font, Mariona Xercavins, Noemí Alonso, Francesco Aiello, María Rivero, Beatriz Piérola, Maider Goikoetxea, María Gracia, Carlos Ibero, Estela Moreno, Jesús Repáraz, Gemma Navarro, Manel Cervantes Garcia, Sonia Calzado Isbert, Marta Navarro Vilasaro, Belen Lopez Garcia, Ignacio de los Santos, Alejandro de los Santos, Jesús Sanz, Lucio García-Fraile, Enrique Martín, Ildefonso Sánchez-Cerrillo, Marta Calvet, Ana Barrios, Azucena Bautista, Carmen Sáez, Marianela Ciudad, Ángela Gutiérrez, Santos del Campo, José Luis Casado, Fernando Dronda, Ana Moreno, M. Jesús Pérez, Sergio Serrano, Ma Jesús Vivancos, Alejandro Vallejo, Matilde Sanchez, Jose Antonio Pérez-Molina, José Manuel Hermida, Antonia Alcaraz, Joaquín Bravo, Ángeles Muñoz, Cristina Tomás, Mónica Martínez, M. Carmen Villalba, Federico García, Clara Martínez, José Hernández, Leopoldo Muñoz Medina, Marta Álvarez, Natalia Chueca, David Vinuesa, Adolfo de Salazar, Ana Fuentes, Emilio Guirao, Laura Viñuela, Andrés Ruiz-Sancho, Francisco Anguita, Jorge Del Romero, Montserrat Raposo, Carmen Rodríguez, Teresa Puerta, Juan Carlos Carrió, Mar Vera, Juan Ballesteros, Oskar Ayerdi, Begoña Baza, Eva Orviz, Antonio Antela, Elena Losada, Melchor Riera, María Peñaranda, M. Angels Ribas, Antoni A. Campins, Mercedes Garcia-Gazalla, Francisco J. Fanjul, Javier Murillas, Francisco Homar, Helem H. Vilchez, Luisa Martin, Antoni Payeras, Jesús Santos, María López, Crisitina Gómez, Isabel Viciana, Rosario Palacios, Luis Fernando López-Cortés, Nuria Espinosa, Cristina Roca, Silvia Llaves, Juan Manuel Tiraboschi, Arkaitz Imaz, Ana Karina Silva, María Saumoy, Sofía Catalina Scévola, Adrián Curran, Vicenç Falcó, Jordi Navarro, Joaquin Burgos, Paula Suanzes, Jorge García, Vicente Descalzo, Patricia Álvarez, Bibiana Planas, Marta Sanchiz, Lucía Rodríguez, M José Sánchez, Javier Pérez, Alfonso del Arco, Javier de la Torre, José Luis Prada, Onofre Juan Martínez, Lorena Martinez, Francisco Jesús Vera, Josefina García, Begoña Alcaraz, Antonio Jesús Sánchez Guirao, Alvaro Mena, Angeles Castro, Berta Pernas, Pilar Vázquez, Soledad López, Sofía Ibarra, Guillermo García, Josu Mirena, Oscar Luis Ferrero, Josefina López, M. Mar Cámara, Mireia de la Peña, Miriam Lopez, Iñigo Lopez, Itxaso Lombide, Victor Polo, Joana de Miguel, Carlos Galera, Marian Fernández, Helena Albendin, Antonia Castillo, Asunción Iborra, Antonio Moreno, M. Angustias Merlos, Asunción Vidal, Concha Amador, Francisco Pasquau, Concepcion Gil, Jose Tomás Algado, Inés Suarez-García, Eduardo Malmierca, Patricia González-Ruano, M. Pilar Ruiz, José Francisco Pascual, Elena Sáez, Luz Balsalobre, M. Villa López, Mohamed Omar, Carmen Herrero, M. Amparo Gómez, Miguel Alberto de Zarraga, Desiré Pérez, Vicente Estrada, Nieves Sanz, Noemí Cabello, Jorge Vergas García, Maria Jose Núñez, Iñigo Sagastagoitia, Miguel Górgolas, Alfonso Cabello, Beatriz Álvarez, Laura Prieto, Irene Carrillo, José Sanz, Alberto Arranz, Cristina Hernández, María Novella, M. José Galindo, Ana Ferrer, Antonio Rivero Román, Inma Ruíz, Antonio Rivero Juárez, Pedro López, Isabel Machuca, Mario Frias, Ángela Camacho, Ignacio Pérez, Diana Corona, Miguel Cervero, Rafael Torres, Juan Antonio Pineda, Pilar Rincón, Juan Macías, Luis Miguel Real, Anais Corma, Alejandro Gonzalez-Serna, Alexandre Pérez, Luis Morano, Celia Miralles, Antonio Ocampo, Guillermo Pousada, Lucía Patiño, Carlos Dueñas, Sara Gutiérrez, Elena Tapia, Cristina Novoa, Xjoylin Egües, and Pablo Telleria
- Subjects
HIV ,Non-AIDS events ,Neoplasia ,Cardiovascular event ,CD4/CD8 ratio ,Medicine ,Medicine (General) ,R5-920 - Abstract
Summary: Background: While a low CD4/CD8 ratio during HIV treatment correlates with immunosenescence, its value in identifying patients at an increased risk for clinical events remains unclear. Methods: We analyzed data from the CoRIS cohort to determine whether CD4 count, CD8 count, and CD4/CD8 ratio at year two of antiretroviral therapy (ART) could predict the risk of serious non-AIDS events (SNAEs) during the next five years. These included major adverse cardiovascular events, non-AIDS-defining malignancies, and non-accidental deaths. We used pooled logistic regression with inverse probability weighting to estimate the survival curves and cumulative risk of clinical events. Findings: The study included 4625 participants, 83% male, of whom 200 (4.3%) experienced an SNAE during the follow-up period. A CD4/CD8 ratio
- Published
- 2023
- Full Text
- View/download PDF
6. Toll-like receptor agonists enhance HIV-specific T cell response mediated by plasmacytoid dendritic cells in diverse HIV-1 disease progression phenotypesResearch in context
- Author
-
Maria R. Jimenez-Leon, Carmen Gasca-Capote, Laura Tarancon-Diez, Beatriz Dominguez-Molina, Macarena Lopez-Verdugo, Ryan Ritraj, Isabel Gallego, Ana I. Alvarez-Rios, Joana Vitalle, Sara Bachiller, María Inés Camacho-Sojo, Alberto Perez-Gomez, Nuria Espinosa, Cristina Roca-Oporto, Mohamed Rafii-El-Idrissi Benhnia, Alicia Gutierrez-Valencia, Luis F. Lopez-Cortes, and Ezequiel Ruiz-Mateos
- Subjects
Plasmacytoid dendritic cells ,TLR agonists ,HIV-Infection ,HIV-1 restriction factors and immunotherapy ,Medicine ,Medicine (General) ,R5-920 - Abstract
Summary: Background: Plasmacytoid dendritic cells (pDCs) sense viral and bacterial products through Toll-like receptor (TLR)-7 and -9 and translate this sensing into Interferon-α (IFN-α) production and T-cell activation. The understanding of the mechanisms involved in pDCs stimulation may contribute to HIV-cure immunotherapeutic strategies. The objective of the present study was to characterize the immunomodulatory effects of TLR agonist stimulations in several HIV-1 disease progression phenotypes and in non HIV-1 infected donors. Methods: pDCs, CD4 and CD8 T-cells were isolated from 450 ml of whole blood from non HIV-1 infected donors, immune responders (IR), immune non responders (INR), viremic (VIR) and elite controller (EC) participants. pDCs were stimulated overnight with AT-2, CpG-A, CpG-C and GS-9620 or no stimuli. After that, pDCs were co-cultured with autologous CD4 or CD8 T-cells and with/without HIV-1 (Gag peptide pool) or SEB (Staphylococcal Enterotoxin B). Cytokine array, gene expression and deep immunophenotyping were assayed. Findings: pDCs showed an increase of activation markers levels, interferon related genes, HIV-1 restriction factors and cytokines levels after TLR stimulation in the different HIV-disease progression phenotypes. This pDC activation was prominent with CpG-C and GS-9620 and induced an increase of HIV-specific T-cell response even in VIR and INR comparable with EC. This HIV-1 specific T-cell response was associated with the upregulation of HIV-1 restriction factors and IFN-α production by pDC. Interpretation: These results shed light on the mechanisms associated with TLR-specific pDCs stimulation associated with the induction of a T-cell mediated antiviral response which is essential for HIV-1 eradication strategies. Funding: This work was supported by Gilead fellowship program, the Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional, FEDER, “a way to make Europe”) and the Red Temática de Investigación Cooperativa en SIDA and by the Spanish National Research Council (CSIC).
- Published
- 2023
- Full Text
- View/download PDF
7. Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered
- Author
-
Luis F. López-Cortés, Abraham Saborido-Alconchel, María Trujillo-Rodríguez, Ana Serna-Gallego, Silvia Llaves-Flores, Esperanza Muñoz-Muela, María Jesús Pérez-Santos, Carmen Lozano, Marta Mejias-Trueba, Cristina Roca, Nuria Espinosa, and Alicia Gutiérrez-Valencia
- Subjects
people living with HIV ,mRNA-1273 vaccine ,BNT162b2 vaccine ,anti-S RBD IgG ,neutralizing antibodies ,SARS-CoV-2 specific B cells ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundData on SARS-CoV-2 mRNA vaccine immunogenicity in people living with human immunodeficiency virus (PLWH) and discordant immune response (DIR) are currently limited. Therefore, we compare the immunogenicity of these vaccines in DIR and immunological responders (IR).MethodsA prospective cohort that enrolled 89 participants. Finally, 22 IR and 24 DIR were analyzed before vaccination (T0), one (T1) and six months (T2) after receiving BNT162b2 or mRNA-1273 vaccine. Additionally, 10 IR and 16 DIR were evaluated after a third dose (T3). Anti-S-RBD IgG, neutralizing antibodies (nAb), neutralization activity, and specific memory B cells were quantified. Furthermore, specific CD4+ and CD8+ responses were determined by intracellular cytokine staining and polyfunctionality indexes (Pindex).ResultsAt T1, all participants developed anti-S-RBD. 100% IR developed nAb compared to 83.3% DIR. Spike-specific B cells were detected in all IR and 21/24 DIR. Memory CD4+ T cells responded in 5/9 IR and 7/9 DIR, mainly based on the expression of IFN-γ and TNF-α, with a higher Pindex in DIR. Memory CD8+ T cells responded in only four participants in each group. At T2, anti-S-RBD and nAb titers were higher in DIR than in IR. In both groups, there was an increase in specific B memory cells, higher in DIR. Six IR and five DIR maintained a specific memory CD4+ response. Memory CD8+ response was preserved in IR but was lost in DIR. In a multivariate linear regression analysis, receiving mRNA-1273 instead of BNT162b2 played a prominent role in the results.ConclusionsOur data suggest that PLWH with DIR can mount an immune response similar to those with higher CD4+, provided they receive the mRNA-1273 vaccine instead of others less immunogenic.
- Published
- 2023
- Full Text
- View/download PDF
8. eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort
- Author
-
Ramón Teira, Helena Diaz-Cuervo, Filipa Aragão, Josefa Muñoz, Pepa Galindo, MaríaDolores Merino, Belén de la Fuente, María Antonia Sepúlveda, Pere Domingo, Josefina García, Manuel Castaño, Esteve Ribera, Paloma Geijo, Alberto Romero, Joaquim Peraire, Elisabeth Deig, Bernardino Roca, Elisa Martínez, Vicente Estrada, Marta Montero, Juan Berenguer, and Nuria Espinosa
- Subjects
hiv ,estimated glomerular filtration rate ,emtricitabine ,tenofovir disoproxil fumarate ,tenofovir alafenamide ,switch ,retrospective ,Infectious and parasitic diseases ,RC109-216 - Abstract
Background: Evidence from clinical practice on the effects of switching from emtricitabine/tenofovir disoproxil fumarate (F/TDF) to emtricitabine/tenofovir alafenamide (F/TAF)-based triple-therapy (TT) regimens on renal parameters is limited. Objective: This retrospective analysis evaluated the effects on renal function of switching from F/TDF to F/TAF-based TT regimens with no change in third agent among people living with HIV (PLWH). Methods: Data were from a multicenter Spanish PLWH cohort. Patients with a baseline estimated glomerular filtration rate (eGFR-EPI) measurement, ≥1 follow-up measurement, ≥30 days treatment with F/TAF, and who switched from F/TDF to F/TAF with no change in third agent were included. Multivariate mixed linear models were used to evaluate change from baseline over time in eGFR-EPI. eGFR-EPI changes before and after switch were analyzed in a matched patient subgroup. Results: Overall, 340 patients were included. Mean (95% CI) eGFR-EPI in patients with baseline eGFR-EPI
- Published
- 2021
- Full Text
- View/download PDF
9. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
- Author
-
Anita Y.M. Howe, Chaturaka Rodrigo, Evan B. Cunningham, Mark W. Douglas, Julia Dietz, Jason Grebely, Stephanie Popping, Javier Alejandro Sfalcin, Milosz Parczewski, Christoph Sarrazin, Adolfo de Salazar, Ana Fuentes, Murat Sayan, Josep Quer, Midori Kjellin, Hege Kileng, Orna Mor, Johan Lennerstrand, Slim Fourati, Velia Chiara Di Maio, Vladimir Chulanov, Jean-Michel Pawlotsky, P. Richard Harrigan, Francesca Ceccherini-Silberstein, Federico Garcia, Marianne Martinello, Gail Matthews, Fay Fabián Fernando, Juan I. Esteban, Beat Müllhaupt, Julian Schulze zur Wiesch, Peter Buggisch, Christoph Neumann-Haefelin, Thomas Berg, Christoph P. Berg, Jörn M. Schattenberg, Christophe Moreno, Rudolf Stauber, Andrew Lloyd, Gregory Dore, Tanya Applegate, Juan Ignacio, Damir Garcia-Cehic, Josep Gregori, Francisco Rodriguez-Frias, Ariadna Rando, Yael Gozlan, Mario Angelico, Massimo Andreoni, Sergio Babudieri, Ada Bertoli, Valeria Cento, Nicola Coppola, Antonio Craxì, Stefania Paolucci, Giustino Parruti, Caterina Pasquazzi, Carlo Federico Perno, Elisabetta Teti, C. Vironet, Anders Lannergård, Ann-Sofi Duberg, Soo Aleman, Tore Gutteberg, Alexandre Soulier, Aurélie Gourgeon, Stephane Chevaliez, Stanislas Pol, Fabrice Carrat, Dominique Salmon, Rolf Kaiser, Elena Knopes, Perpetua Gomes, Rob de Kneght, Bart Rijnders, Mario Poljak, Maja Lunar, Rafael Usubillaga, Carole Seguin_Devaux, Enoch Tay, Caroline Wilson, Dao Sen Wang, Jacob George, Jen Kok, Ana Belén Pérez, Natalia Chueca, Miguel García-Deltoro, Ana María Martínez-Sapiña, María Magdalena Lara-Pérez, Silvia García-Bujalance, Teresa Aldámiz-Echevarría, Francisco Jesús Vera-Méndez, Juan Antonio Pineda, Marta Casado, Juan Manuel Pascasio, Javier Salmerón, Juan Carlos Alados-Arboledas, Antonio Poyato, Francisco Téllez, Antonio Rivero-Juárez, Dolores Merino, María Jesús Vivancos-Gallego, José Miguel Rosales-Zábal, María Dolores Ocete, Miguel Ángel Simón, Pilar Rincón, Sergi Reus, Alberto De la Iglesia, Isabel García-Arata, Miguel Jiménez, Fernando Jiménez, José Hernández-Quero, Carlos Galera, Mohamed Omar Balghata, Joaquín Primo, Mar Masiá, Nuria Espinosa, Marcial Delgado, Miguel Ángel von-Wichmann, Antonio Collado, Jesús Santos, Carlos Mínguez, Felícitas Díaz-Flores, Elisa Fernández, Enrique Bernal, José De Juan, José Joaquín Antón, Mónica Vélez, Antonio Aguilera, Daniel Navarro, Juan Ignacio Arenas, Clotilde Fernández, María Dolores Espinosa, María José Ríos, Roberto Alonso, Carmen Hidalgo, Rosario Hernández, María Jesús Téllez, Francisco Javier Rodríguez, Pedro Antequera, Cristina Delgado, Patricia Martín, Javier Crespo, Berta Becerril, Oscar Pérez, Antonio García-Herola, José Montero, Carolina Freyre, Concepción Grau, Joaquin Cabezas, Miguel Jimenez, Manuel Alberto Macias Rodriguez, Cristina Quilez, Maria Rodriguez Pardo, Leopoldo Muñoz-Medina, and Blanca Figueruela
- Subjects
RAS ,HCV ,DAA ,virologic failure ,NS5A ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background & Aims: Direct-acting antiviral (DAA) regimens provide a cure in >95% of patients with chronic HCV infection. However, in some patients in whom therapy fails, resistance-associated substitutions (RASs) can develop, limiting retreatment options and risking onward resistant virus transmission. In this study, we evaluated RAS prevalence and distribution, including novel NS5A RASs and clinical factors associated with RAS selection, among patients who experienced DAA treatment failure. Methods: SHARED is an international consortium of clinicians and scientists studying HCV drug resistance. HCV sequence linked metadata from 3,355 patients were collected from 22 countries. NS3, NS5A, and NS5B RASs in virologic failures, including novel NS5A substitutions, were examined. Associations of clinical and demographic characteristics with RAS selection were investigated. Results: The frequency of RASs increased from its natural prevalence following DAA exposure: 37% to 60% in NS3, 29% to 80% in NS5A, 15% to 22% in NS5B for sofosbuvir, and 24% to 37% in NS5B for dasabuvir. Among 730 virologic failures, most were treated with first-generation DAAs, 94% had drug resistance in ≥1 DAA class: 31% single-class resistance, 42% dual-class resistance (predominantly against protease and NS5A inhibitors), and 21% triple-class resistance. Distinct patterns containing ≥2 highly resistant RASs were common. New potential NS5A RASs and adaptive changes were identified in genotypes 1a, 3, and 4. Following DAA failure, RAS selection was more frequent in older people with cirrhosis and those infected with genotypes 1b and 4. Conclusions: Drug resistance in HCV is frequent after DAA treatment failure. Previously unrecognized substitutions continue to emerge and remain uncharacterized. Lay summary: Although direct-acting antiviral medications effectively cure hepatitis C in most patients, sometimes treatment selects for resistant viruses, causing antiviral drugs to be either ineffective or only partially effective. Multidrug resistance is common in patients for whom DAA treatment fails. Older patients and patients with advanced liver diseases are more likely to select drug-resistant viruses. Collective efforts from international communities and governments are needed to develop an optimal approach to managing drug resistance and preventing the transmission of resistant viruses.
- Published
- 2022
- Full Text
- View/download PDF
10. High-resolution anoscopy in HIV-infected men: Assessment of the learning curve and factors that improve the performance
- Author
-
Karin Neukam, Yusnelkis Milanés Guisado, María Fontillón, Laura Merino, César Sotomayor, Nuria Espinosa, Luis F. López-Cortés, and Pompeyo Viciana
- Subjects
Infectious and parasitic diseases ,RC109-216 - Abstract
Objective: To determine the required learning time for high-resolution anoscopy (HRA)-guided biopsy to detect histological high-risk squamous intraepithelial lesions (hHSIL) and to identify factors that impact on the training process. Methods: All HIV-infected, screening-naïve men-who-have-sex-with-men who underwent HRA conducted by one single observer from 2010 to 2017 in a Spanish HIV-outpatient clinic were analysed. Results: Eighty-five (14.7%) of the 581 patients included presented hHSIL. The factors associated with the capacity to detect hHSIL [adjusted odds ratio (aOR), 95% confidence interval (95%CI)] were the presence of cytological HSIL (3.04, 1.78–5.21; p
- Published
- 2019
- Full Text
- View/download PDF
11. Repeated Pulses of Methyl-Prednisolone in Adults Hospitalized With COVID-19 Pneumonia and Acute Respiratory Distress Syndrome: A Preliminary Before–After Study (CortiCOVID Study)
- Author
-
Michelle Espinosa-Solano, Demetrio Gonzalez-Vergara, Marta Ferrer-Galvan, Maria Isabel Asensio-Cruz, Jose M. Lomas, Cristina Roca-Oporto, Maria Dolores Navarro-Amuedo, Maria Paniagua-Garcia, Cesar Sotomayor, Nuria Espinosa, Manuel Garcia-Gutierrez, Jose Molina Gil-Bermejo, Manuela Aguilar-Guisado, Manuel Poyato, Julia Praena-Segovia, Alejandro Palomo, Macarena Borrero-Rodriguez, Elisa Cordero, Candela Caballero-Eraso, and Luis Jara-Palomares
- Subjects
COVID-19 ,Neumonía ,Dexametasona ,Síndrome de distrés respiratorio agudo ,Diseases of the respiratory system ,RC705-779 - Abstract
Introduction: The use of systemic corticosteroids in severely ill patients with coronavirus disease 2019 (COVID-19) is controversial. We aimed to evaluate the efficacy and safety of corticosteroid pulses in patients with COVID-19 pneumonia. Methods: A quasi-experimental study, before and after, was performed in a tertiary referral hospital, including admitted patients showing COVID-19-associated pneumonia. The standard treatment protocol included targeted COVID-19 antiviral therapy from 23rd March 2020, and additionally pulses of methylprednisolone from 30th March 2020. The primary outcome was a composite endpoint combining oro-tracheal intubation (OTI) and death within 7 days. Results: A total of 24 patients were included. Standard of care (SOC) (before intervention) was prescribed in 14 patients, while 10 received SOC plus pulses of methylprednisolone (after intervention). The median age of patients was 64.5 years and 83.3% of the patients were men. The primary composite endpoint occurred in 13 patients (92.9%) who received SOC vs. 2 patients (20%) that received pulses of methylprednisolone (odds ratio, 0.02; 95% confidence interval, 0.001 to 0.25; p = 0.019). Length of hospitalization in survivors was shorter in the corticosteroids group (median, 14.5 [8.5–21.8] days vs. 29 [23–31] days, p = 0.003). There were no differences in the development of infections between both groups. There were 3 deaths, none of them in the corticosteroids group. Conclusions: In patients with severe pneumonia due to COVID-19, the administration of methylprednisolone pulses was associated with a lower rate of OTI and/or death and a shorter hospitalization episode. Resumen: Introducción: El uso de corticosteroides sistémicos en pacientes gravemente enfermos por enfermedad coronavírica de 2019 (covid-19) es controvertido. Nuestro objetivo fue evaluar la eficacia y la seguridad de los pulsos de corticoesteroides en los pacientes con neumonía por covid-19. Métodos: Se realizó un ensayo cuasiexperimental, tipo antes y después, en un hospital terciario de referencia que incluyó a pacientes ingresados por neumonía asociada a covid-19. El protocolo de tratamiento estándar incluía un tratamiento antiviral dirigido contra el virus de la covid-19 desde el 23 de marzo de 2020 y añadió pulsos de metilprednisolona desde el 30 de marzo de 2020. El resultado primario fue un criterio combinado compuesto por la intubación orotraqueal y el fallecimiento durante los siguientes siete días. Resultados: Se incluyó un total de 24 pacientes. El protocolo de tratamiento (antes de la intervención) se prescribió en 14 pacientes, mientras que 10 recibieron el protocolo de tratamiento además de los pulsos de metilprednisolona (después de la intervención). La edad media de los pacientes fue de 64,5 años y el 83,3% de los pacientes eran hombres. El resultado combinado primario tuvo lugar en 13 pacientes (92,9%) que recibieron el protocolo de tratamiento frente a 2 pacientes (20%) que recibieron los pulsos de metilprednisolona (odds ratio = 0,02; intervalo de confianza del 95% = 0,001-0,25; p = 0,019). La duración de la hospitalización en los supervivientes fue más corta en el grupo que recibió corticoesteroides (media = 14,5 [8,5-21,8] días frente a 29 [23-31] días, p = 0,003). No hubo diferencias en el desarrollo de infecciones entre ambos grupos. Hubo tres fallecimientos, ninguno de ellos en el grupo que recibió corticoesteroides. Conclusiones: En los pacientes con neumonía grave por covid-19, la administración de pulsos de metilprednisolona se asoció a unas tasas menores de intubación orotraqueal y/o muerte y a episodios de hospitalización más cortos.
- Published
- 2021
- Full Text
- View/download PDF
12. Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV.
- Author
-
Ramón Teira, Helena Diaz-Cuervo, Filipa Aragão, Sophie Marguet, Belén de la Fuente, Maria Jose Muñoz, Nadia Abdulghani, Esteban Ribera, Pere Domingo, Elisabeth Deig, Joaquim Peraire, Bernardino Roca, Marta Montero, Maria José Galindo, Alberto Romero, Nuria Espinosa, Fernando Lozano, María Dolores Merino, Elisa Martínez, Paloma Geijo, Vicente Estrada, Josefina García, M Antonia Sepúlveda, and Juan Berenguer
- Subjects
Medicine ,Science - Abstract
BackgroundSince 1996, the standard of care (SOC) therapy for HIV treatment has consisted of a backbone of two nucleoside analogue reverse transcriptase inhibitors (NRTI) paired with a third agent. Use of two-drug combinations (2DC) has been considered for selected patients to avoid toxicities associated with the use of NRTIs. This study aimed to compare the real-world outcomes of integrase strand transfer inhibitor (INSTI)-containing triple therapy (TT) to dolutegravir- (DTG) and/or boosted protease inhibitor (bPI)-based 2DC in a large Spanish cohort of HIV patients.MethodsA retrospective analysis was performed using data from the VACH cohort, a prospective multicentre Spanish cohort of adult HIV patients. All treatment experienced patients initiating a TT of an INSTI combined with two NRTIs or a 2DC-containing DTG and/or a bPI between 01/01/2012 and 01/06/2017 were included. The unit of analysis was patient-regimens. The overall sample analysis was complemented with two sub-analyses. The first sub-analysis focused on patients treated with a backbone plus DTG compared to those treated with DTG+ one other antiretroviral. The second sub-analysis focused on patients with HIV RNAResultsOverall 7,481 patients were included in the analysis, contributing to 9,243 patient-regimens. Patient characteristics at baseline differed among groups, with the 2DC group being significantly older and having a higher proportion of women, a longer time on ART and a higher number of previous virologic failures. Median (95% Confidence Interval [C.I.]) time to switch was 2.5 years (2.3, 2.7) in 2DC group versus 2.9 years (2.7, 3.0) in TT. Adjusted hazard ratios (95% C.I.) for discontinuation due to any reason, virologic failure and toxicity in the 2DC vs TT group were 1.29 (1.15; 1.44), 2.06 (1.54; 2.77) and 1.18 (0.94; 1.48), respectively. Results were consistent in the two sub-analyses.ConclusionIn this analysis, time to discontinuation and probability of remaining free of virologic failure were significantly higher in patients on INSTI-based TT compared to DTG- and/or bPI-containing 2DC, with no differences in toxicity.
- Published
- 2021
- Full Text
- View/download PDF
13. Spatiotemporal Characteristics of the Largest HIV-1 CRF02_AG Outbreak in Spain: Evidence for Onward Transmissions
- Author
-
Evangelia-Georgia Kostaki, Andreas Flampouris, Timokratis Karamitros, Natalia Chueca, Marta Alvarez, Paz Casas, Belen Alejos, Angelos Hatzakis, Federico Garcia, Dimitrios Paraskevis, CoRIS, Santiago Moreno, Inma Jarrín, David Dalmau, Maria Luisa Navarro, Maria Isabel González, Jose Luis Blanco, Rafael Rubio, Jose Antonio Iribarren, Félix Gutiérrez, Francesc Vidal, Juan Berenguer, Juan González, Belén Alejos, Victoria Hernando, Cristina Moreno, Carlos Iniesta, Luis Miguel Garcia Sousa, Nieves Sanz Perez, M Ángeles Muñoz-Fernández, Isabel María García-Merino, Irene Consuegra Fernández, Coral Gómez Rico, Jorge Gallego de la Fuente, Paula Palau Concejo, Joaquín Portilla, Esperanza Merino, Sergio Reus, Vicente Boix, Livia Giner, Carmen Gadea, Irene Portilla, María Pampliega, Marcos Díez, Juan Carlos Rodríguez, José Sánchez-Payá, Juan Luis Gómez, Jehovana Hernández, María Remedios Alemán, María del Mar Alonso, María Inmaculada Hernández, Felicitas Díaz-Flores, Dácil García, Ricardo Pelazas, Ana López Lirola, José Sanz Moreno, Alberto Arranz Caso, Cristina Hernández Gutiérrez, María Novella Mena, Federico Pulido, Otilia Bisbal, Asunción Hernando, Lourdes Domínguez, David Rial Crestelo, Laura Bermejo, Mireia Santacreu, José Antonio Iribarren, Julio Arrizabalaga, María José Aramburu, Xabier Camino, Francisco Rodríguez-Arrondo, Miguel Ángel von Wichmann, Lidia Pascual Tomé, Miguel Ángel Goenaga, Ma Jesús Bustinduy, Harkaitz Azkune, Maialen Ibarguren, Aitziber Lizardi, Xabier Kortajarena, Mar Masiá, Sergio Padilla, Andrés Navarro, Fernando Montolio, Catalina Robledano, Joan Gregori Colomé, Araceli Adsuar, Rafael Pascual, Marta Fernández, Elena García, José Alberto García, Xavier Barber, Juan Carlos López Bernaldo de Quirós, Isabel Gutiérrez, Margarita Ramírez, Belén Padilla, Paloma Gijón, Teresa Aldamiz-Echevarría, Francisco Tejerina, Francisco José Parras, Pascual Balsalobre, Cristina Diez, Leire Pérez Latorre, Joaquín Peraire, Consuelo Viladés, Sergio Veloso, Montserrat Vargas, Miguel López-Dupla, Montserrat Olona, Anna Rull, Esther Rodríguez-Gallego, Verónica Alba, Marta Montero Alonso, José López Aldeguer, Marino Blanes Juliá, María Tasias Pitarch, Iván Castro Hernández, Eva Calabuig Muñoz, Sandra Cuéllar Tovar, Miguel Salavert Lletí, Juan Fernández Navarro, Jose Miguel Molina, Juan González-garcia, Francisco Arnalich, José Ramón Arribas, Jose Ignacio Bernardino de la Serna, Juan Miguel Castro, Luis Escosa, Pedro Herranz, Victor Hontañón, Silvia García-Bujalance, Milagros García López-Hortelano, Alicia González-Baeza, Maria Luz Martín-Carbonero, Mario Mayoral, Maria Jose Mellado, Rafael Esteban Micán, Rocio Montejano, María Luisa Montes, Victoria Moreno, Ignacio Pérez-Valero, Berta Rodés, Talia Sainz, Elena Sendagorta, Natalia Stella Alcáriz, Eulalia Valencia, José Ramón Blanco, José Antonio Oteo, Valvanera Ibarra, Luis Metola, Mercedes Sanz, Laura Pérez-Martínez, Angels Jaén, Montse Sanmartí, Mireia Cairó, Javier Martinez-Lacasa, Pablo Velli, Roser Font, Mariona Xercavins, Noemí Alonso, Jesús Repáraz, María Gracia Ruiz de Alda, María Teresa de León Cano, Beatriz Pierola Ruiz de Galarreta, Ignacio de los Santos, Jesús Sanz Sanz, Ana Salas Aparicio, Cristina Sarriá Cepeda, Lucio Garcia-Fraile Fraile, Enrique Martín Gayo, José Luis Casado, Fernando Dronda, Ana Moreno, María Jesús Pérez Elías, Cristina Gómez Ayerbe, Carolina Gutiérrez, Nadia Madrid, Santos del Campo Terrón, Paloma Martí, Uxua Ansa, Sergio Serrano, María Jesús Vivancos, Enrique Bernal, Alfredo Cano, Antonia Alcaraz García, Joaquín Bravo Urbieta, Ángeles Muñoz, Maria Jose Alcaraz, Maria del Carmen Villalba, Federico García, José Hernández, Alejandro Peña, Leopoldo Muñoz, David Vinuesa, Clara Martinez-Montes, Fernando García, Carlos Guerrero-Beltran, Jorge Del Romero, Carmen Rodríguez, Teresa Puerta, Juan Carlos Carrió, Mar Vera, Juan Ballesteros, Oskar Ayerdi, Antonio Antela, Elena Losada, Antonio Aguilera, Melchor Riera, María Peñaranda, María Leyes, Ma Angels Ribas, Antoni A Campins, Carmen Vidal, Francisco Fanjul, Javier Murillas, Francisco Homar, Jesús Santos, Crisitina Gómez Ayerbe, Isabel Viciana, Rosario Palacios, Carmen María González, Pompeyo Viciana, Nuria Espinosa, Luis Fernando López-Cortés, Daniel Podzamczer, Elena Ferrer, Arkaitz Imaz, Juan Tiraboschi, Ana Silva, María Saumoy, Julián Olalla, Alfonso del Arco, Javier de la torre, José Luis Prada, José María García de Lomas Guerrero, Javier Pérez Stachowski, Concepción Amador, Onofre Juan Martínez, Francisco Jesús Vera, Lorena Martínez, Josefina García, Begoña Alcaraz, Amaya Jimeno, Angeles Castro Iglesias, Berta Pernas Souto, Alvaro Mena de Cea, Carlos Galera, Helena Albendin, Aurora Pérez, Asunción Iborra, Antonio Moreno, Maria Angustias Merlos, Asunción Vidal, Inés Suárez-García, Eduardo Malmierca, Patricia González-Ruano, Dolores Martín Rodrigo, Mohamed Omar Mohamed-Balghata, Juan A Pineda, Juan Macías, Miguel Thomson, Elena Delgado, Sonia Benito, and Vanessa Montero
- Subjects
HIV-1 ,CRF02_AG ,Spain ,regional dispersal ,spatiotemporal characteristics ,Microbiology ,QR1-502 - Abstract
Background and Aim: The circulating recombinant form 02_AG (CRF02_AG) is the predominant clade among the human immunodeficiency virus type-1 (HIV-1) non-Bs with a prevalence of 5.97% (95% Confidence Interval-CI: 5.41–6.57%) across Spain. Our aim was to estimate the levels of regional clustering for CRF02_AG and the spatiotemporal characteristics of the largest CRF02_AG subepidemic in Spain.Methods: We studied 396 CRF02_AG sequences obtained from HIV-1 diagnosed patients during 2000–2014 from 10 autonomous communities of Spain. Phylogenetic analysis was performed on the 391 CRF02_AG sequences along with all globally sampled CRF02_AG sequences (N = 3,302) as references. Phylodynamic and phylogeographic analysis was performed to the largest CRF02_AG monophyletic cluster by a Bayesian method in BEAST v1.8.0 and by reconstructing ancestral states using the criterion of parsimony in Mesquite v3.4, respectively.Results: The HIV-1 CRF02_AG prevalence differed across Spanish autonomous communities we sampled from (p < 0.001). Phylogenetic analysis revealed that 52.7% of the CRF02_AG sequences formed 56 monophyletic clusters, with a range of 2–79 sequences. The CRF02_AG regional dispersal differed across Spain (p = 0.003), as suggested by monophyletic clustering. For the largest monophyletic cluster (subepidemic) (N = 79), 49.4% of the clustered sequences originated from Madrid, while most sequences (51.9%) had been obtained from men having sex with men (MSM). Molecular clock analysis suggested that the origin (tMRCA) of the CRF02_AG subepidemic was in 2002 (median estimate; 95% Highest Posterior Density-HPD interval: 1999–2004). Additionally, we found significant clustering within the CRF02_AG subepidemic according to the ethnic origin.Conclusion: CRF02_AG has been introduced as a result of multiple introductions in Spain, following regional dispersal in several cases. We showed that CRF02_AG transmissions were mostly due to regional dispersal in Spain. The hot-spot for the largest CRF02_AG regional subepidemic in Spain was in Madrid associated with MSM transmission risk group. The existence of subepidemics suggest that several spillovers occurred from Madrid to other areas. CRF02_AG sequences from Hispanics were clustered in a separate subclade suggesting no linkage between the local and Hispanic subepidemics.
- Published
- 2019
- Full Text
- View/download PDF
14. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
- Author
-
José Manuel Sousa, Mercedes Vergara, Federico Pulido, Gloria Sánchez Antolín, Lander Hijona, Fernando Carnicer, Diego Rincón, Javier Salmerón, Beatriz Mateos-Muñoz, Antoni Jou, Benjamín Polo-Lorduy, Ángel Rubín, Ana Escarda, Patricia Aguilar, Teresa Aldámiz-Echevarría, Luisa García-Buey, José A Carrión, Manuel Hernández-Guerra, Sonia Chimeno-Hernández, Nuria Espinosa, Rosa Mª Morillas, Raúl J Andrade, Manuel Delgado, Adolfo Gallego, Marta Magaz, José María Moreno-Planas, Ángel Estébanez, Mikel Rico, Fernando Menéndez, Blanca Sampedro, Luís Morano, Sonia Izquierdo, José Manuel Zozaya, Manuel Rodríguez, Senador Morán-Sánchez, Sara Lorente, Ignacio Martín-Granizo, Miguel Ángel Von-Wichmann, Marcial Delgado, and Amanda Manzanares
- Subjects
Medicine ,Science - Abstract
AimWe describe the effectiveness and safety of the interferon-free regimen ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin (OBV/PTV/r ± DSV ± RBV) in a nationwide representative sample of the hepatitis C virus (HCV) monoinfected and human immunodeficiency virus-1/hepatitis C virus (HIV/HCV) coinfected population in Spain.Material and methodsData were collected from patients infected with HCV genotypes 1 or 4, with or without HIV-1 coinfection, treated with OBV/PTV/r ± DSV ± RBV at 61 Spanish sites within the initial implementation year of the first government-driven "National HCV plan." Effectiveness was assessed by sustained virologic response at post-treatment week 12 (SVR12) and compared between monoinfected and coinfected patients using a non-inferiority margin of 5% and a 90% confidence interval (CI). Sociodemographic and clinical characteristics or patients and adverse events (AEs) were also recorded.ResultsOverall, 2,408 patients were included in the intention-to-treat analysis: 386 (16%) were patients with HIV/HCV. Patient selection reflected the real distribution of patients treated in each participating region in Spain. From the total population, 96.6% (95% CI, 95.8-97.3%) achieved SVR12. Noninferiority of SVR12 in coinfected patients was met, with a difference between monoinfected and coinfected patients of -2.2% (90% CI, -4.5% - 0.2%). Only genotype 4 was associated with non-response to OBV/PTV/r ± DSV ± RBV treatment (pConclusionsOur results confirm that OBV/PTV/r ± DSV ± RBV is effective and generally well tolerated in a representative sample of the HCV monoinfected and HCV/HIV coinfected population in Spain within the experience of a national strategic plan to tackle HCV.
- Published
- 2019
- Full Text
- View/download PDF
15. Impact of the COVID-19 Pandemic on Antimicrobial Consumption and Hospital-Acquired Candidemia and Multidrug-Resistant Bloodstream Infections
- Author
-
Ana Belen Guisado-Gil, Carmen Infante-Domínguez, Germán Peñalva, Julia Praena, Cristina Roca, María Dolores Navarro-Amuedo, Manuela Aguilar-Guisado, Nuria Espinosa-Aguilera, Manuel Poyato-Borrego, Nieves Romero-Rodríguez, Teresa Aldabó, Sonsoles Salto-Alejandre, Maite Ruiz-Pérez de Pipaón, José Antonio Lepe, Guillermo Martín-Gutiérrez, María Victoria Gil-Navarro, José Molina, Jerónimo Pachón, José Miguel Cisneros, and On behalf of the PRIOAM Team
- Subjects
COVID-19 ,antimicrobial stewardship ,anti-infective agents ,bacteremia ,candidemia ,Therapeutics. Pharmacology ,RM1-950 - Abstract
During the COVID-19 pandemic, the implementation of antimicrobial stewardship strategies has been recommended. This study aimed to assess the impact of the COVID-19 pandemic in a tertiary care Spanish hospital with an active ongoing antimicrobial stewardship programme (ASP). For a 20-week period, we weekly assessed antimicrobial consumption, incidence density, and crude death rate per 1000 occupied bed days of candidemia and multidrug-resistant (MDR) bacterial bloodstream infections (BSI). We conducted a segmented regression analysis of time series. Antimicrobial consumption increased +3.5% per week (p = 0.016) for six weeks after the national lockdown, followed by a sustained weekly reduction of −6.4% (p = 0.001). The global trend for the whole period was stable. The frequency of empirical treatment of patients with COVID-19 was 33.7%. No change in the global trend of incidence of hospital-acquired candidemia and MDR bacterial BSI was observed (+0.5% weekly; p = 0.816), nor differences in 14 and 30-day crude death rates (p = 0.653 and p = 0.732, respectively). Our work provides quantitative data about the pandemic effect on antimicrobial consumption and clinical outcomes in a centre with an active ongoing institutional and education-based ASP. However, assessing the long-term impact of the COVID-19 pandemic on antimicrobial resistance is required.
- Published
- 2020
- Full Text
- View/download PDF
16. No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.
- Author
-
Alicia Gutierrez-Valencia, Coral García, Pompeyo Viciana, Yusnelkis Milanés-Guisado, Tamara Fernandez-Magdaleno, Nuria Espinosa, Juan Pasquau, and Luis Fernando López-Cortés
- Subjects
Medicine ,Science - Abstract
BACKGROUND:Simplification strategies of antiretroviral treatment represent effective tools for the reduction of drug-induced toxicity, resistance mutations in case of virological failure and costs. OBJECTIVES:To assess the effectiveness of simplification to atazanavir/ritonavir (ATVrtv) or unboosted atazanavir (ATV400) plus lamivudine, and if low plasma or intracellular ATV Ctrough influence virological outcomes. METHODS:Ambispective observational study in patients with undetectable HIV-RNA who were switched to ATVrtv or ATV400 plus lamivudine once daily. Previous virological failures (VF) were allowed if the resistance tests showed major resistance mutation neither to ATV nor to lamivudine. VF was defined as two consecutive plasma HIV-RNA >200 copies/mL. Effectiveness was assessed by intention-to-treat and on-treatment analyses. Plasma and intracellular ATV Ctrough were measured by LC-MS/MS. RESULT:A total of 246 patients were included. At week 48, the Kaplan-Meier estimation of efficacy within the ATVrtv and ATV400 groups were 85.9% [95% confidence interval, (CI95), 80.3-91.4%] versus 87.6% (CI95, 80.1-94.1%) by intention-to-treat analysis (p = 0.684), and 97.7% (CI95, 95.2-100%) versus 98.8% (CI95, 97.0-100%) by on-treatment analysis (p = 0.546), respectively. Plasma and intracellular Ctrough were significantly higher with ATVrtv than with ATV400 (geometric mean (GM), 318.3 vs. 605.9 ng/mL; p = 0.013) and (811.3 vs. 2659.2 ng/mL; p = 0.001), respectively. Only 14 patients had plasma Ctrough below the suggested effective concentration for ATV (150 ng/mL). No relationship between plasma or intracellular Ctrough and VF or blips were found. CONCLUSION:Boosted or unboosted ATV plus lamivudine is effective and safe, and the lower plasma Ctrough observed with ATV400 do not compromise the effectiveness of these simplification regimens in long-term virologically suppressed HIV-1-infected patients.
- Published
- 2018
- Full Text
- View/download PDF
17. Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis.
- Author
-
Lize Cuypers, Ana Belén Pérez, Natalia Chueca, Teresa Aldamiz-Echevarría, Juan Carlos Alados, Ana María Martínez-Sapiña, Dolores Merino, Juan Antonio Pineda, Francisco Téllez, Nuria Espinosa, Javier Salméron, Antonio Rivero-Juarez, María Jesús Vivancos, Víctor Hontañón, Anne-Mieke Vandamme, and Féderico García
- Subjects
Medicine ,Science - Abstract
Despite high response rates associated to hepatitis C virus (HCV) treatment, no protective immunity is acquired, allowing for reinfection and continued infectiousness. Distinguishing between relapse and reinfection is crucial for patient counselling and to choose the most appropriate retreatment. Here, refined phylogenetic analysis using multiple genes served to assess genotype and reinfection for 53 patients for whom the virus was sampled before start of therapy and at time of sustained virological response evaluation at week 12. At baseline, genotypes were determined as HCV1a (41.5%), HCV1b (24.5%), HCV4 (18.9%) and HCV3a (15.1%), while six cases revealed to be discordantly assigned by phylogeny and commercial assays. Overall, 60.4% was co-infected with HIV. The large majority was classified as people who inject drugs (78.6%), often co-infected with HIV. Transmission was sexual in seven cases, of which five in HIV-positive men-who-have-sex-with-men. Overall, relapse was defined for 44 patients, while no conclusion was drawn for four patients. Five patients were reinfected with a different HCV strain, of which three with a different genotype, showing that phylogeny is needed not only to determine the genotype, but also to distinguish between relapse and intra-subtype reinfection. Of note, phylogenies are more reliable when longer fragments of the viral genome are being sequenced.
- Published
- 2018
- Full Text
- View/download PDF
18. Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment.
- Author
-
Yusnelkis Milanés-Guisado, Alicia Gutiérrez-Valencia, María Trujillo-Rodríguez, Nuria Espinosa, Pompeyo Viciana, and Luis Fernando López-Cortés
- Subjects
Medicine ,Science - Abstract
OBJECTIVES:To analyse the correlation and concordance between aCD4, CD4%, CD4/CD8, their intra-patient variability, and to compare the immune recovery (IR) rates based on the three parameters in HIV-infected patients after starting antiretroviral therapy. METHODS:From a prospectively followed cohort, patients who maintained HIV-RNA suppression in ≥95% of the determinations throughout the follow-up were selected. IR was defined as aCD4 >650/μl, CD4% ≥38% or CD4/CD8 ≥1. RESULTS:A total of 1164 patients with a median follow-up of 5 years were analysed. The increases in aCD4, CD4% and CD4/CD8 were highest during the first year and considerably lower thereafter regardless of baseline aCD4. The annual increases in aCD4 showed poor correlations with those of CD4% (r = 0.143-0.250) and CD4/CD8 (r = 0.101-0.192) but were high between CD4% and CD4/CD8 (r = 0.765-0.844; p650/μl, CD4% ≥38%, and CD4/CD8 ≥1, respectively, while only 31% achieved both aCD4 and CD4/CD8 target values. CONCLUSIONS:The increases in aCD4 poorly correlate with those of CD4% and CD4/CD8. IR rates based on aCD4 significantly overstate those obtained by CD4% and CD4/CD8. CD4% and CD4/CD8 are more stable markers than aCD4 and should be taken into account to monitor the IR after treatment initiation.
- Published
- 2018
- Full Text
- View/download PDF
19. Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study.
- Author
-
Karin Neukam, Nuria Espinosa, Antonio Collado, Marcial Delgado-Fernández, Patricia Jiménez-Aguilar, Antonio Rivero-Juárez, Victor Hontañón-Antoñana, Ana Gómez-Berrocal, Josefa Ruiz-Morales, Dolores Merino, Ana Carrero, Francisco Téllez, María José Ríos, José Hernández-Quero, María de Lagarde-Sebastián, Inés Pérez-Camacho, Francisco Vera-Méndez, Juan Macías, Juan A Pineda, and hEPAtic Study Group
- Subjects
Medicine ,Science - Abstract
OBJECTIVES:The aim of this study was to evaluate the frequency of transaminase elevations (TE) and total bilirubin elevations (TBE) during the first year of therapy with a single tablet regimen including RPV/FTC/TDF (EPA) in HIV/hepatitis C virus (HCV)-coinfected subjects in clinical practice. METHODS:In a retrospective analysis, HIV/HCV-coinfected subjects who started EPA at 17 centres throughout Spain were included as cases. Subjects who started an antiretroviral therapy (ART) other than EPA during the study period at the same hospitals were randomly selected as controls in a 1:2 ratio. Primary outcome variables were grade (G) 3-4 TE and G4 TBE. RESULTS:Of the 519 subjects included, 173 individuals started EPA. Nine (5.2%) subjects of the EPA group and 49 (14.2%) controls were naïve to ART. The median (Q1-Q3) follow-up was 11.2 (9.7-13.9) months. TE was observed in 2 [1.2%; 95% confidence interval (CI): 0.14%-4.1%] subjects receiving EPA and 11 (3.2%; 95%CI: 1.6%-5.6%) controls (p = 0.136), all events were G3. No patient discontinued ART due to TE. One (0.6%; 95%CI: 0.01%-3.1%) subject on EPA and 8 (2.3%; 95%CI: 1%-4.5%) subjects in the control group developed TBE (p = 0.141), without developing any other hepatic event during follow-up. Three (2.3%) subjects with cirrhosis versus 10 (3.1%) without cirrhosis showed G3-4 TE (p = 0.451). CONCLUSION:The frequency of severe liver toxicity in HIV/HCV-coinfected subjects receiving EPA under real-life conditions is very low, TE were generally mild and did not lead to drug discontinuation. All these data suggest that EPA can be safely used in this particular subpopulation.
- Published
- 2016
- Full Text
- View/download PDF
20. Prevalence of non-alcoholic fatty liver disease in a multicentre cohort of people living with HIV in Spain
- Author
-
Jordi Navarro, Adrian Curran, Berta Raventós, Jorge García, Paula Suanzes, Vicente Descalzo, Patricia Álvarez, Nuria Espinosa, Marisa Luisa Montes, Inés Suárez-García, Concha Amador, Roberto Muga, Vicenç Falcó, and Joaquín Burgos
- Subjects
Internal Medicine - Published
- 2023
21. Incidence Rate and Risk Factors for Anal Squamous Cell Carcinoma in a Cohort of People Living With HIV from 2004 to 2017: Implementation of a Screening Program
- Author
-
Karin Neukam, Cristina Roca, Pompeyo Viciana, Luis F. López-Cortés, Yusnelkis Milanés Guisado, Nuria Espinosa, María Fontillón, Ana Domínguez Castaño, and Cesar Sotomayor
- Subjects
Adult ,Male ,medicine.medical_specialty ,HIV Infections ,Efficiency, Organizational ,Rate ratio ,Men who have sex with men ,Cohort Studies ,Sexual and Gender Minorities ,Risk Factors ,Internal medicine ,Humans ,Mass Screening ,Outpatient clinic ,Medicine ,Neoplasm Staging ,business.industry ,Incidence ,Incidence (epidemiology) ,Gastroenterology ,Anal Squamous Cell Carcinoma ,HIV ,General Medicine ,Middle Aged ,Anus Neoplasms ,Confidence interval ,Spain ,Case-Control Studies ,Cohort ,Carcinoma, Squamous Cell ,Female ,business ,Follow-Up Studies ,Cohort study - Abstract
Anal squamous cell carcinoma is rare, in general, but considerably higher in HIV-infected men who have sex with men. There is no consensus on the screening of at-risk populations.This study aimed to determine the incidence rates of anal squamous cell carcinoma and the efficacy of a screening program.This is a cohort study (SeVIHanal/NCT03713229).This study was conducted at an HIV outpatient clinic in Seville, Spain.From 2004 to 2017, all patients with at least 1 follow-up visit were analyzed (follow-up group), including a subgroup of men who have sex with men who participated in a specialized program for screening and treating anal neoplasia (SCAN group) from 2011 onward.The primary outcome measure was the incidence rate of anal squamous cell carcinoma.Of the 3878 people living with HIV included in the follow-up group, 897 were transferred to the SCAN group; 1584 (41%) were men who have sex with men. Total follow-up was 29,228 person-years with an overall incidence rate for anal squamous cell carcinoma of 68.4/100,000 person-years (95% CI, 46.7-97.4). The changes in the incidence rate/100,000 person-years (95% CI) over time was 20.7 (3.40-80.5) for 2004 to 2006, 37.3 (13.4-87.3) for 2007 to 2010, and 97.8 (63.8-144.9) for 2011 to 2017 (p0.001). The strongest impact on the incidence of anal squamous cell carcinoma was made by the lack of immune restoration (adjusted incidence rate ratio (95% CI): 6.59 (4.24-10); p0.001), the Centers for Disease Control and Prevention category C (adjusted incidence rate ratio (95% CI): 7.49 (5.69-9.85); p0.001), and non-men who have sex with men (adjusted incidence rate ratio (95% CI): 0.07 (0.05-0.10); p0.001) in a Poisson analysis. From 2010 to 2017, incidence rates (95% CI) of anal squamous cell carcinoma within the SCAN group and the men who have sex with men of the follow-up group were 95.7 (39.6-202) and 201 (101-386)/100,000 person-years (adjusted incidence rate ratio (95% CI): 0.30 (0.23-0.39); p0.001). The incidence rate ratio (95% CI) including non-men who have sex with men in the follow-up group was 0.87 (0.69-1.11); p = 0.269.Adherence to the visits could not be quantified.Incidence rates of anal squamous cell carcinoma in people living with HIV increased significantly from 2004 to 2017, especially in men who have sex with men who were not being screened. Participation in the SCAN program significantly reduced the incidence of anal squamous cell carcinoma in men who have sex with men, in whom focus should be placed, especially on those presenting with Centers for Disease Control and Prevention category C and advanced immune suppression. See Video Abstract at http://links.lww.com/DCR/B734.ANTECEDENTES:El carcinoma anal a células escamosas es generalmente raro, pero considerablemente más alto en hombres infectados por el VIH que tienen relaciones sexuales con hombres. No hay consenso sobre el cribado de poblaciones en riesgo.OBJETIVO:Este estudio tuvo como objetivo determinar las tasas de incidencia del carcinoma anal a células escamosas y la eficacia de un programa de detección.DISEÑO:Estudio de cohorte (SeVIHanal / NCT03713229).AJUSTE:Clínica ambulatoria de VIH en Sevilla, España.PACIENTES:De 2004 a 2017, se analizaron todos los pacientes con al menos una visita de seguimiento (grupo F / U), incluido un subgrupo de hombres que tenían relaciones sexuales con hombres que participaron en un programa especializado de cribado y tratamiento de neoplasias anales (SCAN-group) a partir de 2011.PRINCIPALES MEDIDAS DE RESULTADO:Tasas de incidencia del carcinoma anal a células escamosas.RESULTADOS:De las 3878 personas que viven con el VIH incluidas en el grupo F / U, 897 fueron transferidas al grupo SCAN, 1584 (41%) eran hombres que tenían relaciones sexuales con hombres. El seguimiento total fue de 29228 personas-año con una tasa de incidencia general de carcinoma anal a células escamosas de 68,4 / 100000 personas-año [intervalo de confianza del 95%: 46,7-97,4]. El cambio en las tasas de incidencia / 100000 personas-año (intervalo de confianza del 95%) a lo largo del tiempo fue 20,7 (3,40-80,5) para 2004-2006, 37,3 (13,4-87,3) para 2007-2010 y 97,8 (63,8-144,9) para 2011-2017, p0,001. El impacto más fuerte en la incidencia del carcinoma a células escamosas anal fue la falta de restauración inmunológica [índice de tasa de incidencia ajustado (intervalo de confianza del 95%): 6,59 (4,24-10); p0,001], categoría C de los Centros de Control de Enfermedades [índice de tasa de incidencia ajustado (intervalo de confianza del 95%): 7,49 (5,69-9,85); p0,001] y no hombres que tenían relaciones sexuales con hombres [razón de tasa de incidencia ajustada (intervalo de confianza del 95%): 0,07 (0,05-0,10); p0,001] en el análisis de Poisson. Desde 2010-2017, las tasas de incidencia (intervalo de confianza del 95%) de carcinoma anal a células escamosas dentro del grupo SCAN y los hombres que tienen relaciones sexuales con hombres del grupo F / U fueron 95,7 (39,6-202) y 201 (101- 386) / 100000 personas-año [razón de tasa de incidencia ajustada (intervalo de confianza del 95%): 0,30 (0,23-0,39); p0,001]. La razón de la tasa de incidencia (intervalo de confianza del 95%), incluidos los no hombres que tenían relaciones sexuales con hombres en F / U, fue de 0,87 [0,69-1,11); p = 0,269].LIMITACIONES:No se pudo cuantificar la adherencia a las visitas.CONCLUSIÓNES:La tasa de incidencia del carcinoma anal a células escamosas en personas que viven con el VIH aumentó significativamente de 2004 a 2017, especialmente en hombres que tenían relaciones sexuales con hombres que no se someten a pruebas de detección. La participación en el programa SCAN redujo significativamente la incidencia de carcinoma anal a células escamosas en hombres que tenían relaciones sexuales con hombres, en quienes se debe prestar una especial atención, sobre todo en aquellos que se presentan en la categoría C de los Centros de Control de Enfermedades con inmunodeficiencia avanzada. Consulte Video Resumen en http://links.lww.com/DCR/B734.
- Published
- 2021
22. TLR Agonists Enhance HIV-Specific T-Cell Response Mediated by Plasmacytoid Dendritic Cells in Diverse HIV-1 Disease Progression Phenotypes
- Author
-
Maria Reyes Jimenez-Leon, Carmen Gasca-Capote, Laura Tarancon-Diez, Beatriz Dominguez-Molina, Macarena Lopez-Verdugo, Ryan Ritraj, Ana Isabel Alvarez-Rios, Joana Vitallé, Sara Bachiller, Alberto Pérez-Gómez, Nuria Espinosa, Cristina Roca-Oporto, Mohamed Rafii-El-Idrissi Benhnia, Alicia Gutierrez-Valencia, Luis Fernando López-Cortés, and Ezequiel Ruiz-Mateos
- Abstract
Plasmacytoid dendritic cells (pDCs) sense microbial products through TLR-7 and -9 and translate this sensing in Interferon-α (IFN-α) production and T-cell polarization. The understanding of the mechanisms involved in pDCs stimulation may contribute to immunotherapeutic strategies aiming to decrease HIV-1 reservoir. Here, we characterize the immunomodulatory effects of TLR agonist stimulations through a pDC/T-cell coculture in different HIV-1 disease progression phenotypes and healthy donors (HD). pDCs were previously stimulated with AT-2-HIV-1, CpGA, CpGC and GS9620. After coculture with autologous CD4 or CD8 T-cells we observed an increase of pDCs activation markers levels, interferon related genes, HIV-1 restriction factors and cytokines levels. This pDCs coordinate activation was prominent with CpGC and GS9620 and induced an increase of HIV-specific T-cell response. These results shed light on the mechanisms associated with TLR-specific pDCs stimulation associated with T cell polarization for eliciting antiviral response which is essential for HIV eradication strategies.
- Published
- 2022
23. Toll-like Receptor Agonists Enhance HIV-specific T Cell Response Mediated by Plasmacytoid Dendritic Cells in Diverse HIV-1 Disease Progression Phenotypes
- Author
-
Ezequiel Ruiz-Mateos, Maria Reyes Jimenez-Leon, Carmen Gasca-Capote, Laura Tarancon-Diez, Beatriz Dominguez-Molina, Macarena Lopez-Verdugo, Ryan Ritraj, Ana Isabel Alvarez-Rios, Joana Vitallé, Sara Bachiller, Alberto Pérez-Gómez, Nuria Espinosa, Cristina Roca-Oporto, Mohamed Rafii-El-Idrissi Benhnia, Alicia Gutierrez-Valencia, and Luis Fernando López-Cortés
- Abstract
Plasmacytoid dendritic cells (pDCs) sense viral and bacterial products through Toll-like receptor (TLR)-7 and -9 and translate this sensing in Interferon-α (IFN-α) production and T cell polarization. These cells are considered a link between innate and adaptive immunity, inducing and maintaining antigen-specific T cell responses and contributing to the control and eventually to the chronic immune activation and disease progression in HIV-1 infection scenario. The understanding of the mechanisms involved in pDCs stimulation may contribute to immunotherapeutic strategies aiming to decrease HIV-1 reservoir. The objective of the present study was to characterize the immunomodulatory effects of TLR agonist stimulations through a pDC/T cell coculture in different HIV-1 disease progression phenotypes and healthy donors (HD). pDCs were previously stimulated with AT-2-HIV-1, CpGA, CpGC and GS9620. After coculture with autologous CD4 or CD8 T cells we observed an increase of pDCs activation markers levels, interferon related genes, HIV-1 restriction factors and cytokines levels. This pDCs coordinate activation was prominent with CpG-C and GS9620 and induced an increase of HIV-specific T cell response. This pDCs dependent HIV-1 specific T-cell response was associated with the upregulation of HIV-1 restriction factors and IFN-α production. Interestingly, pDCs activation in people on ART was similar to that found in people that spontaneously control the virus. These results shed light on the mechanisms associated with TLR-specific pDCs stimulation associated with T cell polarization for eliciting antiviral response which is essential for HIV eradication strategies.
- Published
- 2022
24. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world
- Author
-
Ana María Martínez-Sapiña, Concepción Grau, Maria Rios, Javier Crespo, Óscar Pérez, Elisa Fernández, Antonio Rivero-Juárez, Carlos Mínguez, Juan Carlos Alados-Arboledas, Miguel Jimenez, Joaquín Primo, Antonio Poyato, Juan Manuel Pascasio, Mónica Vélez, Natalia Chueca, Juan Arenas, Javier Salmerón, Berta Becerril, José Luis Montero, María Dolores Ocete, Clotilde Fernández, Marta Casado, Sergi Reus, Teresa Aldámiz-Echevarría, Carolina Freyre, Pedro Antequera, María Jesús Vivancos-Gallego, Carmen Hidalgo, Miguel Angel Simón, Cristina Delgado, Alberto de la Iglesia, Dolores Merino, Enrique Bernal, Mar Masiá, José Hernández-Quero, Daniel Navarro, Nuria Espinosa, Carlos Galera, Federico García, Ana Belén Pérez, Antonio Aguilera, Jesús Santos, Patricia Martín, Fernando Jiménez, María Jesús Téllez, José Miguel Rosales-Zábal, Silvia García-Bujalance, Juan A. Pineda, María Magdalena Lara-Pérez, Francisco Téllez, Marcial Delgado, Pilar Rincón, Francisco Javier Rodríguez, Roberto Alonso, José De Juan, Antonio García-Herola, María Dolores Espinosa, Antonio Collado, Francisco Jesús Vera-Méndez, Rosario Hernández, José Joaquin Antón, Miguel Ángel Von-Wichmann, Miguel García-Deltoro, Isabel García-Arata, Felicitas Diaz-Flores, Mohamed Omar Balghata, Instituto de Salud Carlos III, European Commission, Fundación Progreso y Salud, Junta de Andalucía, and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
- Subjects
Cyclopropanes ,Male ,0301 basic medicine ,Pyrrolidines ,Sustained Virologic Response ,Sofosbuvir ,Resistance testing ,Hepacivirus ,Viral Nonstructural Proteins ,Direct-acting antivirals ,chemistry.chemical_compound ,0302 clinical medicine ,Resistance-associated substitution ,Anilides ,Prospective Studies ,Sulfonamides ,education.field_of_study ,Imidazoles ,virus diseases ,Valine ,Hepatitis C ,Middle Aged ,Retreatment ,HCV ,Cohort ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,medicine.drug ,Cohort study ,RASs ,medicine.medical_specialty ,Genotype ,Proline ,Lactams, Macrocyclic ,Voxilaprevir ,Population ,Antiviral Agents ,03 medical and health sciences ,Internal medicine ,Drug Resistance, Viral ,Ribavirin ,medicine ,Humans ,education ,Fluorenes ,Ritonavir ,Hepatology ,business.industry ,medicine.disease ,digestive system diseases ,Regimen ,030104 developmental biology ,Treatment failure ,chemistry ,Spain ,Benzimidazoles ,Carbamates ,business - Abstract
GEHEP-004 Study Group: María Dolores Ocete, Miguel Ángel Simón, Pilar Rincón, Sergi Reus, Alberto De la Iglesia, Isabel García-Arata, Miguel Jiménez, Fernando Jiménez, José Hernández-Quero, Carlos Galera, Mohamed Omar Balghata, Joaquín Primo, Mar Masiá, Nuria Espinosa, Marcial Delgado, Miguel Ángel von-Wichmann, Antonio Collado, Jesús Santos, Carlos Mínguez, Felícitas Díaz-Flores, Elisa Fernández, Enrique Bernal, José De Juan, José Joaquín Antón, Mónica Vélez, Antonio Aguilera, Daniel Navarro, Juan Ignacio Arenas, Clotilde Fernández, María Dolores Espinosa, María José Ríos, Roberto Alonso, Carmen Hidalgo, Rosario Hernández, María Jesús Téllez, Francisco Javier Rodríguez, Pedro Antequera, Cristina Delgado, Patricia Martín, Javier Crespo, Berta Becerril, Óscar Pérez, Antonio García-Herola, José Montero, Carolina Freyre, Concepción Grau., [Background & Aims] Most hepatitis C virus (HCV)-infected patients failing NS5A inhibitors develop resistance-associated substitutions (RASs). Here we report the use of resistance-guided retreatment of patients who failed prior NS5A inhibitor-containing regimens in the GEHEP-004 cohort. This is the largest direct-acting antiviral (DAA)-resistance cohort study conducted in Spain. We aim to provide indications on how to use resistance information in settings where sofosbuvir/velpatasvir/voxilaprevir may not be available., [Methods] GEHEP-004 is a prospective multicenter cohort enrolling HCV-infected patients treated with interferon (IFN)-free DAA regimens. Prior to retreatment, population-based sequencing of HCV NS3, NS5A and NS5B genes was performed. After receiving a comprehensive resistance interpretation report, the retreatment regimen was chosen and the sustained virological response (SVR) at 12 weeks after treatment completion (SVR12) was recorded., [Results] A total of 342 patients experiencing virological failure after treatment with sofosbuvir/ledipasvir±ribavirin (54%), sofosbuvir/daclatasvir±ribavirin (23%), or paritaprevir-ritonavir/ombitasvir±dasabuvir±ribavirin (20%) were studied. After a resistance report, 186 patients were retreated. An SVR12 was achieved for 88.1% of the patients who failed after sofosbuvir/ledipasvir±ribavirin, 83.3% of the patients who failed after sofosbuvir/daclatasvir±ribavirin, 93.7% of the patients who failed after paritaprevir-ritonavir+ombitasvir±dasabuvir±ribavirin., [Conclusions] In our study, we show how resistance-guided retreatment in conjunction with an interpreted report allows patients to achieve SVR rates close to 90%. We hypothesize that SVR rates may even be improved if resistance data are discussed between experienced virologists and treating clinicians. We believe that our data may be relevant for countries where the access to new DAA combination regimens is limited., [Lay summary] Hepatitis C infection can be cured with currently available antiviral agents. Only a small proportion of patients experience treatment failure, however, in absolute numbers, a high number of patients may require retreatment. Highly effective combinations of antivirals are also available for retreatment. However, these antivirals might not be available in resource-limited settings. Herein, we show how, by analyzing the cause of resistance, retreatment efficacy with old drugs can get very close to the efficacy of new drug combinations., This work was supported in part by grants from Fondo de Investigación Sanitaria (www.isciii.es) (PI15/00713), Plan Nacional de I+D+I and Fondo Europeo de Desarrollo Regional-FEDER (www.redes/redes/inicio) (RD16/0025/0040), Fundación Progreso y Salud, Junta de Andalucia (http://www.juntadeandalucia.es/fundacionprogresoysalud/es) (PI-0411-2014), and GEHEP-SEIMC (GEHEP-004).
- Published
- 2019
25. Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort
- Author
-
Ramón Teira, Helena Diaz-Cuervo, Filipa Aragão, Manuel Castaño, Alberto Romero, Bernardino Roca, Marta Montero, Maria José Galindo, Maria Jose Muñoz-Sánchez, Nuria Espinosa, Joaquim Peraire, Elisa Martínez, Belén de la Fuente, Pere Domingo, Elisabeth Deig, María Dolores Merino, Paloma Geijo, Vicente Estrada, María Antonia Sepúlveda, Josefina García, Juan Berenguer, Adriá Currán, [Teira R] Service of Internal Medicine, Hospital de Sierrallana, Torrelavega, Spain. [Diaz-Cuervo H] Gilead Sciences, MAOR, London, UK. [Aragão F] Maple Health Group, New York City, NY, USA. NOVA National School of Public Health, Public Health Research Centre, Unversidade NOVA de Lisboa, Lisboa, Portugal. [Castaño M] Hospital Regional Universitario de Málaga, Málaga, Spain. [Romero A] Hospital Universitario de Puerto Real, Puerto Real, Spain. [Roca B] Hospital General de Castellón, Castellón, Spain. [Deig E] Hospital General de Granollers, Granollers, Spain. [Currán A] Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Hospital General de Granollers
- Subjects
Microbiology (medical) ,virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Lentivirus::infecciones por VIH [ENFERMEDADES] ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,HIV ,Effectiveness ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,Infectious Diseases ,Virologic failure ,Adverse events ,Time to discontinuation ,Medicaments - Efectes fisiològics ,Medicaments - Eficàcia ,VIH (Virus) - Tractament ,Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::HIV Infections [DISEASES] ,Two-drug combinations ,Triple therapy - Abstract
Introduction Standard therapy for HIV treatment has consisted of two nucleoside analogue reverse transcriptase inhibitors (NRTI) paired with a third agent. Use of two-drug regimens (2DR) has been considered for selected patients in part to avoid toxicities associated with the use of NRTIs. This study aimed to compare the real-world outcomes of integrase inhibitor (INSTI)-based three-drug regimens (3DR) versus 2DR of dolutegravir (DTG) + rilpivirine (RPV) or DTG + lamivudine (3TC). Methods All patients in the Spanish VACH cohort switching to INSTI-based 3DR or a 2DR consisting of DTG + RPV or DTG + 3TC between May 2, 2016 and May 15, 2019 were included. Kaplan-Meier curves and Cox proportional hazard models were used to assess time to/risk of discontinuation due to treatment failure (TF) (defined as virologic failure [VF], immunologic failure, or disease progression) and adverse events (AEs). Three secondary analyses were performed: (1) in restricting the analysis to patients who were virologically suppressed (HIV RNA < 50 copies/mL) at switch; (2) matched analysis (2:1, matched by age, sex, number of previous VFs, and line of regimen), and (3) using VF as the primary endpoint in all patients. Results Overall, 5047 3DR and 617 2DR patients were analyzed. Baseline characteristics differed between groups; 2DR patients were older, more treatment experienced, and more likely to be virologically suppressed at switch. Time to discontinuation due to TF was significantly shorter for 2DR (P = 0.002). The hazard ratio (HR) for discontinuation due to TF on 2DR vs 3DR was 2.33 (P = 0.003). No difference was observed for time to discontinuation (P = 0.908) or risk of discontinuation due to AEs (HR = 0.80; P = 0.488). Results were qualitatively similar in virologically suppressed patients, matched analysis, and for VF. Conclusion In the real world, the risks of discontinuation due to TF and VF were more than two times higher in patients switching to DTG-based 2DR than INSTI-based 3DR, with no difference in discontinuation due to AEs. Plain Language Summary People living with HIV (PLHIV) need lifelong treatment to prevent progression to AIDS. Standard HIV treatments use three different drugs in combination, but these can potentially cause unwanted side effects. Treatments using just two drugs have been developed. These aim to reduce side effects and treat HIV effectively. This study included 5664 participants in Spain who were split into two groups: 5047 participants switched from their old treatment to a three-drug regimen (3DR), and 617 participants switched to a two-drug regimen (2DR). The researchers measured how long it took for the participants to stop taking their treatment because it was not working, or it caused too many side effects. At the end of the study, more than 70% of participants in either group were still taking the same treatment. Of the 30% of participants who stopped treatment because it stopped working, those taking a 2DR stopped sooner than those taking a 3DR. This difference started to appear at about 18 months and got bigger until the study ended, which was 3 years after starting treatment. Participants taking a 2DR were twice as likely to stop treatment because it was not working than those taking a 3DR. There was no difference between the groups for how long it took for participants to stop their treatment because of side effects. These results show that for some PLHIV, the 2DR stopped working sooner than 3DR, without the benefit of fewer side effects.
- Published
- 2021
26. Pérdidas de seguimiento de personas con infección por el VIH en la cohorte española VACH en el periodo 2013-2014: importancia de los factores sociodemográficos
- Author
-
Fernando Lozano de León, M. José Galindo, Elisabeth Deig, Elisa Martínez, Francisco Téllez, Mar Gutierrez, Marta Montero, Ramón Teira, Pepa Muñoz-Sánchez, Nuria Espinosa, Joaquim Peraire, and Francisco Gonzalez
- Subjects
0301 basic medicine ,Microbiology (medical) ,03 medical and health sciences ,0302 clinical medicine ,030106 microbiology ,030212 general & internal medicine - Abstract
Resumen Objetivo Determinar la proporcion de personas con infeccion por VIH o sida que se encontraban en seguimiento en la cohorte VACH en 2012 y que resultaron perdidas del mismo en 2013 y 2014, asi como establecer las caracteristicas sociodemograficas relacionadas con dicha perdida. Metodos Consideramos perdidos del seguimiento a los sujetos con menos de un registro de consulta por ano analizado. Construimos modelos de regresion logistica para la estimacion de las razones de ventajas (odds ratio [OR]) y sus intervalos de confianza del 95% (IC del 95%) de las variables relacionadas con la perdida de seguimiento. Resultados El porcentaje global de perdidas en seguimiento fue del 15,5% (IC del 95%: 14,9-16,1). Las variables asociadas con la perdida de seguimiento fueron no recibir tratamiento antirretroviral (TAR) (OR: 1,948; IC del 95: 1,651-2,298), ser inmigrante (OR: 1,746; IC del 95: 1,494-2,040), el consumo de farmacos por via intravenosa como mecanismo de transmision del VIH (OR: 1,498; IC del 95: 1,312-1,711), encontrarse en situacion de desempleo (OR: 1,331; IC del 95: 1,179-1,503), no tener pareja (OR: 1,948, IC del 95: 1,651-1,298), pertenecer a un estrato socioeconomico bajo (OR: 1,279; IC del 95: 1,143-1,431) y ser atendido en un hospital con menos de 1.000 pacientes en seguimiento (OR: 1,257; IC del 95%: 1,121-1,457), ademas de menor edad y menos tiempo de seguimiento en la cohorte. Conclusiones El 15,5% de los pacientes fueron perdidos del seguimiento en un periodo de 2 anos en la cohorte VACH. Ello se asocio a una serie de variables sociodemograficas y epidemiologicas, cuya identificacion puede ser util para disenar iniciativas focalizadas sobre las poblaciones mas susceptibles de abandonar los circuitos asistenciales y a orientar estrategias disenadas a la consecucion del objetivo 90-90-90.
- Published
- 2019
27. Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV
- Author
-
Filipa Aragão, Joaquim Peraire, Juan Berenguer, Pere Domingo, Belén de la Fuente, Sophie Marguet, María José Galindo, María Dolores Merino, Vicente Estrada, Fernando Lozano, Josefina Garcia, Ramón Teira, Esteban Ribera, Nadia Abdulghani, Helena Diaz-Cuervo, Bernardino Roca, Maria Jose Muñoz, Marta Montero, Elisa Martínez, M. Antonia Sepúlveda, Alberto Romero, Nuria Espinosa, Elisabeth Deig, Paloma Geijo, Institut Català de la Salut, [Teira R] Hospital de Sierrallana, Torrelavega, Spain. [Diaz-Cuervo H] Gilead Sciences, Medical Affairs, Stockley Park HEOR, Spain. [Aragão F] Maple Health Group, New York, New York, United States of America. NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Lisboa, Portugal. [Marguet S] Amaris Consulting, Health Economics and Market Access (HEMA), Levallois-Perret, France. [de la Fuente B] Hospital de Cabueñes, Gijón, Spain. [Muñoz MJ] Hospital de Basurto, Bilbao, Spain. [Ribera E] Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
0301 basic medicine ,DOLUTEGRAVIR ,RNA viruses ,Male ,Viral Diseases ,HIV Infections ,Pathology and Laboratory Medicine ,Toxicology ,Biochemistry ,chemistry.chemical_compound ,0302 clinical medicine ,Medical Conditions ,ANTIRETROVIRAL THERAPY ,Immunodeficiency Viruses ,Nucleic Acids ,terapéutica::farmacoterapia::farmacoterapia combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Medicine and Health Sciences ,Public and Occupational Health ,030212 general & internal medicine ,Prospective Studies ,INFECTED PATIENTS ,Multidisciplinary ,Protease Inhibitor Therapy ,Hazard ratio ,Therapeutics::Drug Therapy::Drug Therapy, Combination [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,HIV diagnosis and management ,Standard of Care ,Middle Aged ,Viral Load ,Vaccination and Immunization ,AIDS ,Drug Combinations ,Infectious Diseases ,Medical Microbiology ,Research Design ,Viral Pathogens ,Dolutegravir ,Cohort ,Viruses ,Medicine ,Reverse Transcriptase Inhibitors ,Female ,virus::virus ARN::Retroviridae::Lentivirus::Lentivirus de los primates::VIH [ORGANISMOS] ,Pathogens ,Research Article ,medicine.medical_specialty ,PHASE-3 ,Clinical Research Design ,Anti-HIV Agents ,Science ,030106 microbiology ,Immunology ,Antiretroviral Therapy ,Research and Analysis Methods ,Microbiology ,03 medical and health sciences ,Antiviral Therapy ,Internal medicine ,Retroviruses ,medicine ,Humans ,Microbial Pathogens ,Survival analysis ,SUPPRESSION ,Retrospective Studies ,Toxicity ,Proportional hazards model ,business.industry ,Lentivirus ,Organisms ,diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Biology and Life Sciences ,HIV ,Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Confidence interval ,Diagnostic medicine ,Discontinuation ,Regimen ,chemistry ,Medicaments - Eficàcia ,Viruses::RNA Viruses::Retroviridae::Lentivirus::Lentiviruses, Primate::HIV [ORGANISMS] ,HIV-1 ,RNA ,Preventive Medicine ,Adverse Events ,Medicaments - Administració ,business ,Persones seropositives - Abstract
Teràpia antiretroviral; Diagnòstic i gestió del VIH; Teràpia amb inhibidors de la proteasa Terapia antirretroviral; Diagnóstico y gestión del VIH; Terapia con inhibidores de la proteasa Antiretroviral therapy; HIV diagnosis and management; Protease inhibitor therapy Background Since 1996, the standard of care (SOC) therapy for HIV treatment has consisted of a backbone of two nucleoside analogue reverse transcriptase inhibitors (NRTI) paired with a third agent. Use of two-drug combinations (2DC) has been considered for selected patients to avoid toxicities associated with the use of NRTIs. This study aimed to compare the real-world outcomes of integrase strand transfer inhibitor (INSTI)-containing triple therapy (TT) to dolutegravir- (DTG) and/or boosted protease inhibitor (bPI)-based 2DC in a large Spanish cohort of HIV patients. Methods A retrospective analysis was performed using data from the VACH cohort, a prospective multicentre Spanish cohort of adult HIV patients. All treatment experienced patients initiating a TT of an INSTI combined with two NRTIs or a 2DC-containing DTG and/or a bPI between 01/01/2012 and 01/06/2017 were included. The unit of analysis was patient-regimens. The overall sample analysis was complemented with two sub-analyses. The first sub-analysis focused on patients treated with a backbone plus DTG compared to those treated with DTG+ one other antiretroviral. The second sub-analysis focused on patients with HIV RNA
- Published
- 2021
28. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study
- Author
-
Jaime Fernández-Bujarrabal Villoslada, Beatriz Dietl Gómez-Luengo, Daniel Ortiz-Sánchez, José Ramón Blanco Ramos, Bartolomé Gómez-Arroyo, Martín Sebastián Ruiz Grinspan, Ester Sáez de Adana Arróniz, Daniel Daniel López, Judit Villar-García, Begoña De Dios García, Josefina García García, Nuria Rabella García, Ana Rodríguez-Revillas, Lydia Martín González, Mercedes San Franco, Elena Martinez Robles, Teresa González Alegre, Elena Morcillo Rodríguez, Oriol Gasch Blasi, Laura Prieto Pérez, Isabel Jiménez Martínez, Elena Isaba Ares, Ricardo Deza-Palacios, Helena Mendez del Sol, Melchor Riera Jaume, Mercedes Rodriguez-Gutiérrez, Daniel Podzamczer, Mikel Urroz, Luis Ramos Ruperto, María Paniagua, Sergio Alcolea-Batres, Mar Masiá Canuto, Rubén Soriano-Arroyo, Paloma Merino Amador, Berta Antón-Huguet, Gabriela Alcaraz, Pablo Ryan, Carlos Franco, Leyre Díez-Porres, Juan Carlos Figueiras, Sara Lidia Kamal, Mónica Hernández, Lorena Barrera-López, Germán Ramírez-Olivencia, Kapil Laxman Nanwani Nanwani, Alberto Oreja, Montserrat Laguno, José Javier Castrodeza Sanz, Belén Loeches Yagüe, Maria Vargas, Luis Eduardo López-Cortés, Isabel Gutiérrez, Sara Vela Berna, P. Martín, Miguel Pedromingo Kus, Jesús Sanz Sanz, Mº Antonia Sepúlveda Berrocal, Carmen Yera Bergua, Juan Cuadros González, Julen Cadiñanos Loidi, Josefa Serralta Buades, María Concepción Prados Sánchez, Francesca Gioia, Iris Pedrola Gorrea, Francisco Arnaiz de las Revillas, Xabier Kortajarena Urkola, Laia Lorenzo-Esteller, Ruth Bravo-Lizcano, Angel Iniesta, Sofía González-García, Belén Martínez López, Agustín Rojas-Vieyra, Concepción García García, Raquel Cavallé-Pulla, Lucía Gómez García, Alicia Herrero, Carlos Jesús Dueñas Gutiérrez, Loreto Vidaur Tello, Carmen Fernández-Capitán, Victoria Lo-Iacono García, Cecilia Gómez-Domínguez, Adalgisa Falcone, María José Ruiz Rodríguez, Arancha Castellano, Miquel Hortos Alsina, María Concepción Nuñez, María Luisa Fernández Vidal, Jésica Abadia Otero, Natalia Moya-González, Albert Sabater Gil, Pedro de la Oliva, Ylenia María Conde-Alonso, Laura Castelo Corral, José Mº García de Lomas Guerrero, Verónica Pérez-Blanco, Isabel San Juan, Martina Archinà, Júlia Sellarés, Juan Carlos Ramos, Cintia María Martínez Mateu, Belén Fernández-Puntero, Andrea Torrecillas-Mainez, Luis Falgueras López, Carlos Carpio-Segura, María Gandullo-Moro, Francisco Abellán Martínez, Cristina Díez, Pilar Martín Dávila, Silvia Gómez-Zorrilla, María Pilar García García, Renzo Tejada-Sorados, María Dolores del Toro, E. Álvarez-Rojas, Gema Muñiz, Lucía Cajuela, María Novella Mena, Estel Pons Viñas, Andrea Pérez Rodríguez, Benito Almirante, Mónica Gozalo, Patricia Girón De Velasco-Sada, Camilo Sanz Zamudio, Ángeles García Flores, Joaquín López-Contreras González, Blanca Fabre-Estremera, Pelayo Fernández Cidón, María Martínez-Redondo, Paula Alejandra Hernández-Liebo, Juan Herrero, Marta Duque-Alcorta, María Teresa García Morales, Concepción Amador Prous, Alex Soriano, Raquel Hernando Nieto, Raquel Álvarez Franco, Alfonso Cabello Úbeda, Luis Force Sanmartín, Laura Mao Martín, Daniel Prieto-Arribas, Mario Pérez-Butragueño, Pere Domingo Pedrol, Henar Serrano-Martín, Mónica Zubimendi, M. Rodríguez-Rubio, David Pujol-Pocull, Manuel García-Gutiérrez, Carlos Manrique de Lara, Lucy Abella Vázquez, Marta Navarro Vilasaró, Carlota Cascajares-Sanz, Berta Torres, Daniel Ceniza-Pena, Isidro Moreno Gómez-Limón, María Rodríguez Mahía, Alí Martakoush, Antonio Buño-Soto, Patricia Serrano de la Fuente, Claudia González Rico, Teresa Pedraz, Conchita Pérez-Jorge Peremarch, Elena Trigo Esteban, Rosana Rouco Esteves Marques, Juan Mora Delgado, Inés Pérez Zapata, Sandra Pérez-Recio, María Ángeles Domínguez, Manuel Cervantes García, Francisco Reinoso-Lozano, M. Martí De Gracia, Carmina Oltra, Beatriz Pérez-Monte Mínguez, Guillermina Bejarano-Redondo, Sara Heili Frades, María Paz García Butenegro, Miguel Torralba González de Suso, Elena Álvaro-Alonso, Víctor J Moreno Cuerda, Gonzalo Garzón, Marcelo Daltro-Lage, Alberto Serrano Martínez, José María Aguado, Mar Mosquera, Ruth Figueroa Cerón, Juan Carlos Martin Gutiérrez, Javier Oliver Ortega, Esteban Martínez, Cristina Gómez-Ayerbe, Nerea Carrasco Antón, María Carmen Fariñas Álvarez, José Antonio Ruiz, Justo Menéndez, Lucía Díaz, José L. Casado, Pilar Vizcarra, Javier Veganzones, Miguel Ángel Moran Rodríguez, Mercedes López-Martinez, Emilio Letang, Paloma Romero Gallego-Acho, Julia Vasquez-Manau, Alexander Rombauts, Marta Robledo del Prado, Luis Puente, Beatriz Alvarez, Juan Emilio Losa García, José Tomas Algado Rabasa, Rafael Torres Perea, Angélica Rivera-Núñez, Esther Expósito Palomo, Antonio J. Carcas, Lucía Platero-Dueñas, Irene Martín Rubio, Miguel Salavert Lletí, Claudia García-Vaz, Antonio Martínez-Verdasco, Jorge Díaz-Garzón, Javier Nieto Arana, Fernando Cadenas-Gota, Richard Rojas, Abelardo García de Lorenzo, Juan Carlos López, Pedro Luis Martinez Hernández, Manuela de Pablos-Gómez, Pablo Alonso, Enrique Seco, María García-López, Lorena López-Corcuer, Celia Blasco-Andres, Delia Romera-Cano, José M. Azcona Gutiérrez, Almudena Gutiérrez-Arroyo, Paula Mendoza Roy, Ignacio De los Santos Gil, Miguel Angel Sánchez-Castellano, Sara Medrano Pardo, Mikel del Álamo Martínez de Lagos, Rocío Martínez Avilés, Elisabet Martínez-Cerón, José Manuel Vázquez Comendador, Marta Virgós-Varela, Alejandra Álvarez Brandt, Carmen Herrero Rodríguez, Jorge Martínez Jordán, Antonio Rezusta López, Marta Vizcaíno Callejón, Manuela Simon-Velasco, Jorge Ignacio Alonso-Eiras, Elisa García Vázquez, Mercè Gurguí Ferrer, Mónica González Bardanca, Nataly Cancelliere-Fernández, José Luis Díaz de Tuesta del Arco, María Larrosa, Alejandro García García, Carmen Román-Hernández, Elena Calvin-García, José Sanz Moreno, Miguel Silvestre-Niño, Nieves Valcarce Pardeiro, Maria Teresa Corcuera-Pindado, Enrique Monteoliva, Aina Gabarrell Pascuet, Elena María Aranda Rife, Aina Gomila Grange, Alba Alastrué Violeta, Daniel Roger Zapata, Jaime Montserrat, Eduardo Malmierca Corral, Marco Palma, Blanca Martínez Cifre, Gema Domínguez de Pablos, Emilio Cuesta, Eva Perales, Silvia Hernáez Crespo, Juan Torres-Macho, Adrián Sánchez Montalvá, Rocío Montejano Sánchez, Eva Van den Eynde Otero, Silvia Castañeda Espinosa, Virginia Pérez Doñate, Adriana Hernández Belmonte, Laura Iglesias Llorente, María Sanz de Pedro, Juan Espinosa Pereiro, Lubna Dani Ben-Abdellah, Raquel Barrós González, Iván Piñero, Araceli López-Tofiño, Ana Such-Diaz, Karim Mohamed Ramírez, Pilar Toledano Sierra, Rebeca Izquierdo, Guillermo Cuevas, Andrés Felipe Cardona Arias, Ileana Gabriela-Tomoiu, David Vinuesa García, Ander González Sarria, Stephan Stuart, José María Fernández, Javier Torres-Cortés, Elisabet Delgado Sánchez, María Varela-Cerdeira, Gemma Bassani, Berta Román Bernal, Isabel García, Paula Betancort de la Torre, Yolanda Martínez-Abad, Beatriz Arizcun, Juan José Cabanillas-Martín, Guillermo Estrada Fernández, Oscar del Río Pérez, Inmaculada Martín Pérez, Andony García, Luis Gómez-Carrera, Alexander Agrifoglio, Alberto M. Borobia, Jordi Niubó, Vanessa Alende Castro, Lara Montes Andújar, Alexandra De la Vega, Efrén Sánchez Vidal, Isabel A. Pérez Hernández, Laura Frade-Pardo, Ana Josefa Tebar-Martinez, Silvia Álvarez Kaelis, Sara De la Fuente Moral, Luz Martin Carbonero, Juan Cantón De Seoane, María Dolores Montero-Vega, Juan Carlos Gainzarain Arana, Sergio España Cueto, Rocío Nuñez-Cabetas, María Sánchez-Martín, Constanza Muñoz Hornero, Ana Gómez-Zamora, Javier Díaz Luperena, Patricia González-Donapetry, José Miguel Cisneros, Lucía Hernández-Rivas, Patricia González Ruano, Andrea Espigares Correa, Rocío González-León, Nicolás García-Arenzana, Omar Cervera, Andrés Canut Blasco, Ana Isabel Cañabate, Mercedes Villarreal García-Lomas, Melania Íñigo Pestaña, Maria Álvarez de Castro, Ana Correa Ruiz, Belén Civantos, Lydia Pascual-García, Paula Villares Fernández, Mikel Rico-Briñas, María José Alcaide-Martín, Adoración Valiente, Victoria Arnalich-Montiel, Pilar Retamar, Jesús Mingorance, Eva María Romay Lema, Pablo Galindo-Ballesteros, M. Teresa Pérez-Rodríguez, Rosario Maria Torres Santos-Olmo, Inmaculada Pinilla, Elie Dahdouh, Beatriz Tejero-Soriano, Cristina Pizarro-Sanchez, Félix Gutiérrez Rodero, Luis Jara-Palomares, María Hernández-Gancedo, Cristina Chico Chumillas, Sergio Gilaberte Reyzábal, Manuel González-Viñolis, Ana Martínez Sapiña, Francisco Parras, Teresa Rubio Obanos, Iker Falces-Romero, Adriana Sánchez Serrano, Teresa Álvarez de Espejo Montiel, Jorge Valencia, Miquel Pujol, José Luis Velasco Garrido, Belén Calderón-Llopis, Álvaro Varela Plaza, Abel Caro, Juan José González-Garcia, Miguel Sampedro Núñez, María Fernández-Velilla, Emilio Cendejas-Bueno, María Cecilia Cánepa, José Luis Santiago Blanco, Alicia Rico-Nieto, Mónica Liébana Gómez, Sarah Caro Bragado, Susana Sánchez-Rico, José María Marimón Ortiz de Zárate, Paloma Dorao, Cristina Plaza-Moreno, Isabel Valbuena, Natividad Benito Hernández, Ginger Giorgiana Cabrera Tejada, Jordi Carratalà, Sara Fernández Rodríguez, Vicente Ferrer Díaz De Brito Fernández, Pilar Catalán, Pablo Mariscal-Aguilar, Germán Daroca-Bengoa, Rafael Fernandez, Raquel Casitas-Mateo, Ester Zamarrón de Lucas, Úrsula Quesada, Julio Yagüe, María Isabel Quijano Contreras, Trinidad Baselga-Puente, Lourdes Herrera Pacheco, Carlota Gudiol, Alazne Lartategi Iraurgi, Estefanía Martinez-Chavez, Silvia Valero Rovira, Alba Bergas, Zaida Ruiz de Azua, Teresa Prim, Cristina García-Quero, Pilar Hernández Machín, Rubén Gomez-Rioja, María Pavón-Masa, María de las Mercedes Valentín-Pastrana Aguilar, Ilduara Pintos Pascual, Lucía Brieba-Plata, María Jesús Domínguez Santalla, Francisco Javier Membrillo de Novales, Raúl Galera-Martínez, Ana Lérida Urteaga, Miguel Cervero, Alberto Mangas-Moro, José Hernández Quero, Teresa Sancho Bueso, María Angustias Quesada Simón, Luz Parra-Gordo, Sofía Díaz-Carrasco, Juan Carlos Abad Almendro, Andrés Javier Ruiz Fernández, Estíbaliz Molina Iturritza, Aurea Díez-Tascón, Yale Tung-Chen, Marta Rava, Carlos Villasante, Gabriel Gaspar Alonso-Vega, Clara Cabré-Verdiell Surribas, Esther Fraile Villarejo, Aida Gutiérrez García, Ana Robustillo-Rodela, Rafael Padrós Selma, Jesús Rodríguez-Baño, Frank Perdomo-García, Lydia de la Fuente Regaño, María del Mar Arenas-Miras, Cristina Rodríguez Roca, Blanca Montero-San Martín, Gema Crespo-Sánchez, Miguel Ramírez-Verdyguer, Alberto Diaz de Santiago, Marta Díaz Menéndez, María de la Luz Padilla Salazar, Silvia Arribas-Terradillos, Sadaf Zafar Iqubal-Mirza, Isabel Rábago Lorite, Belén Estébanez, Maite Ganchegui Aguirre, André Barbosa Ventura, Estefanía Fernandez-Cerezo, Maria Eulalia Valencia, Zaira R. Palacios-Baena, Beatriz Diaz Pollan, Lidia Martín, Sara Fabra-Cadenas, José Miguel Cantero-Escribano, Carmen Busca Arenzana, Emilia Guasch-Arévalo, Virginia Fernández Espinilla, Ainhoa Urrutia Losada, Oscar Noya González, Raquel Aranega, Alejandro Rodríguez Saenz de Urturi, María Jesús Jaras Hernandez, Charbel Maroun Eid, Marta Mora Rillo, Antonio Ramos Martínez, Meritxell Ortega Montoliu, Jose María Mostaza, Sonia García Calvo, Cristina Verdú, Celia Salamanca, Cristina Cervera Acedo, Mónica Martínez, Miren Urrestarazu Larrañag, Carmen Barroso Castro, Ivo Vives-Beltrán, Lorea Arteche Eguizabal, Ana Montero, Javier Balsa Vázquez, Amparo Perez-Garcia Morillón, Alejandra Pérez García, Isabel Pérez-Tamayo, Rafael Cantón Moreno, Antonio Marín-García, Inmaculada Jarrín, Núria Trullen, Ines Fernandez-Jimenez, Guillermo Ruiz-Carrascosa, Almudena Villa Martí, Jamil Cedeño, Marcos Díez Martínez, Carlos Lahoz, Lorena De la Mora, Javier Sánchez-Lora, Ana María Martínez-Virto, Irene Sanjosé Muñiz, Adrian Peña-Hidalgo, Cristina López Mestanza, Carola Gutiérrez, Ana Laila Qasem-Moreno, Irene Salvo García, Lucía Fernández de Orueta, Jorge Parra Ruiz, Sergio Pérez Pinto, Carlos García-Mochales Fortún, Esteban García de las Heras, Patricia González Muñiz, Mario Fernández-Ruiz, Anna Ferrer Santolaria, Olga Sánchez Pernaute, Julieta Latorre, Jesús Manzanares, Miguel Angel Martinez Gallego, Helena Notario, Ángel Rodríguez-Villodres, Eva Fernández-Bretón, Encarnación Moral Escudero, Mónica Sánchez-Santiuste, Carmen Martínez Cilleros, Ricardo Fernández Roblas, María Yllescas, Eva Soria-Alcaide, Marta Arsuaga Vicente, Marta Gómez-López, Regina Cabrera-Gamero, Natalia Carrasco Fons, Diana Piñar Cabezos, Begoña Sánchez-Sánchez, Francisca Garcia-Iglesias, Raquel Marín-Baselga, Alberto Arranz Caso, Virginia Guedez-López, Lucia Boix Palop, Íñigo Gredilla Zubiría, María Hidalgo-Sánchez, Laura López-Tappero Irazábal, José Ignacio Bernardino de la Serna, Javier Queiruga, Natalia Guadalupe Barrera-López, María López-Jodar, Jorge Calderón Parra, Diego Rodríguez-Álvarez, José Molina, María Luisa Montes, Beatriz Rodríguez-Alonso, Daniel Useros Brañas, Maria Gracia Liras-Hernández, Lucía Romero-Imaz, Nieves Jaén Sánchez, Marta Segovia-Amaro, Marta Vara, Maribel Zamora Cintas, Montaña Jiménez Álvaro, Alberto Moreno Fernandez, Asunción Díaz, Jordi Mancebo Cortés, Francisco Javier De Castro Vega, Álvaro Navarro Batet, Francisco Javier Sagra, Alexandre Pérez González, Luis Castro, Isabel Barrio López, Marta Ruiz-Alguero, Silvia Ossaba-Vélez, Alberto Martín-Vega, Maria Jesus Bustinduy Odriozola, Sivia Pastor-Yvorra, Nuria Espinosa, Elena Múñez Rubio, María E García-Leoni, Sandra Rosillo, Cristina Carbonell, Iván Navas Clemente, Paula Arriola Martínez, Marta Peña, Lucía Martínez de Soto, Roberto Mora-Corcovado, Alberto Iglesias-Sigüenza, Rocío Ruíz-Hueso, Elena Alvar, Pedro Camacho, Jesús Sojo-Dorado, Remedios Alemán Valls, Ines Ponz, Esmeralda Palmier Peláez, María Arcos Rueda, Guillermo Maestro de la Calle, Ramón Pérez Tanoira, Ana Martínez Vidal, Cristina Amodeo, Marina Pacheco Martínez-Atienza, Clara Muñoz Aguirre, Felipe Villar Álvarez, Giorgina Salgueiro, Xavier Sanz Salvador, César Pérez-Romero, Beatriz Álvarez Zapatero, Nelsa González-Aguado, Robert Torres Sánchez del Arco, Enrique Míguez Rey, Merce Sirisi, Xavier Bonfill Cosp, Marta Yagüe-Barrado, Elena Pérez-Costa, Sandra Casares, Eva Estirado, Jorge Alvarez Troncoso, Cristina Martín-Carrasco, Diana Sande Llovo, Melchor Álvarez de Mon Soto, Arantzazu Mera Fidalgo, Francisco Marqués-González, Agustín Valido-Morales, Luis Alberto Nieto Fernández del Campo, Helem Haydee Vilchez, María Rivas-Carmenado, Francisco Moreno, Ignacio Fernández-Fernández, Henar Calvo Sánchez, Ana González-Cordón, Isabel Fernández-Navarro, María Simón Sacristán, Eva Jiménez-González de Buitrago, M. Muñoz, María Laplaza-González, Rosa de Miguel Buckley, Marta Redondo-Gutierrez, Paula Santibáñez Sáenz, Raquel Martínez Goñi, Marta Rico Rodríguez, Carlos Toro-Rueda, Francisco Arnalich, Ana Santiago-Recuerda, Clara Soto Abanedes, María Dolores Herrero Mendoza, Aquilino Sanchez Purificación, Diego Franch Llasat, María Velasco Arribas, Alejandro Martín-Quirós, Jorge Alba Fernández, Elena Ramírez, Amparo López-Bernus, Marta Alvarado, María Rexach Fumaña, Martín Pilares-Barco, Carmen Liébana Martos, Yolanda Martínez Martínez, Nicolas Merchante Gutiérrez, Maria José Asensio, Ianire Virto Peña, Lucía Mejuto-Illade, María Angeles Martinez-López, Pilar López-Pirez, Alejandro Suárez, Cristóbal Manuel Rodríguez Leal, Sara Garcia-Bellido Ruiz, Jorge Guisández Martín, Lucia Cachafeiro, Pedro Gil Divasson, Almudena Quintás-Viqueira, Laura Currás-Sánchez, Alverio Seiz-Martinez, Mario Ruiz-Bastián, Juan José Menéndez, Jorge Orihuela Martín, María Dolores Nieto Martín, Cristina Arévalo, Rebeca Marinas, Susana Casas Rodríguez, Zuriñe Ortiz de Zárate Ibarra, Yolanda Posada Franco, Joan Gómez-Junyent, Ana María Garijo Saiz, Marina Alguacil-Guillén, Ana Alguacil, Esther Aznar Muñoz, Sara Bañón Escandell, Juan Salillas Hernando, Chiara Fanciulli, Rosa Gómez-Gil, Francisco García-Río, Moncef Belhassen-García, Belén Gutierrez Sancerni, Sonia Vega Molpeceres, Inés Suárez-García, Leire Pérez-Latorre, Elena Chamarro Martí, Carmen Rosario Herrero Gil, Belén Gutiérrez-Gutiérrez, Tatiana Mata Forte, Francesca Sánchez Martínez, Lucía Ramos Merino, Santiago Yus, Mº Ángeles Marcos, Susana Martínez-Álvarez, Alexy Inciarte, Manuel Quintana-Díaz, Lucía Serrá, Belén Alejos, Guillem Policarpo Torres, José Román Muñoz del Rey, Irene Blanco-Bartolomé, Alberto Bahamonde Carrasco, Victoria Hernando, Jhon Rojas, David Roa, María Ángeles Garcinuño, Aránzazu Villasante de la Puente, Patricia Pérez-Palacios, Jesús Ruiz Aragón, Valvanera Ibarra Cucalón, Lucía Ortega Enciso, Ismail Zakariya-Yousef Breval, Jorge Navarro López, Gema Barbeito Castiñeiras, Clara Sala Jofre, Nora Molina Torres, Manuel Poyato, Inmaculada Poquet Catala, Virginia Pomar Solchaga, María Pilar Romero-Gómez, Clara Hernández, Helena Mozas Moriñigo, Mercedes Guillamón Sánchez, Zineb Karroud, Arianna Catino, Violeta Ramos Sesma, Santos del Campo, Pilar Fernández-Calle, Ana Fernández Cruz, Fernando Salvador, Rosa Mayayo-Alvira, Pilar Barco Núñez, Ana Isabel Peláez Ballesta, Silvia Suárez Diaz, Beatriz María Sanjuan, Nora Izko Gartzia, Teresa Aldámiz-Echevarría, Cecilia Tortajada Alamilla, Pau Bosch-Nicolau, María del Mar Alonso Socas, Sonia Calzado Isbert, Jose R. Arribas, Juan Fernández-Lahera, Elizabet Petkova Saiz, Eva Jiménez, Gabriela Abelenda-Alonso, Alba Ribera Puig, Pascual Sanabria-Carretero, Sara Rodrigo González, Irene Díaz de la Torre, Tamara Manso Gómez, Carmen Sáez Barberá, Roi Suárez Gil, Paloma García-Clemente, Héctor Meijide Míguez, Elsa Izquierdo-García, Josune Goikoetxea Agirre, Olalla Martínez Macia, Jesús Santos González, Guillermo Jiménez Álvarez, Cristina Marcelo-Calvo, Javier Coy Coy, Isabel Arenas-Berenguer, Julio García Rodríguez, Natalia Yustas-Benitez, Sarai Quirós-Fernández, Marina Noguerol-Gutiérrez, María Adalid Moll, Iván Bloise-Sánchez, Mario José Rodriguez Dominguez, Elena Salamanca, Francisco Mora Gómez, Lucio García-Fraile, Pablo Millán, C Gutiérrez, Montserrat Rodríguez, José Antonio Oteo Revuelta, Joseba Portu Zapirain, Cristina Moreno, Irene Carrillo Acosta, Jorge Calvo, Ana Mariño Callejo, David Romero-Ribate, Blanca Alonso, Elena Muñoz del Val, Elena Resino Foz, Olaia Rodriguez-Fraga, Miguel Villamarín, Irene Amores-Hernández, Laura Muñoz López, Esther García Almodóvar, Ismael Casares Guerrero, Angélica Villanueva-Freije, Nuria Parra Arribas, Montserrat Sanmarti Vilamala, Macarena Lerín-Baratas, Mercedes Castro-Martínez, Melissa Carreres Candela, Lucia Suárez Pérez, Jose Manuel Iturzaeta-Sánchez, Thamires Silva-Freire, José Antonio Peregrina, María Luisa Machado Sicilia, Sergio Zurita, Daniel Molina Morant, Olga González-Peña, Fernando Lázaro-Perona, Paloma Oliver-Saez, Beatriz Mestre-Gómez, Luis Díaz Díez Picazo, Silvia García-Bujalance, Francisco Rodríguez Gómez, Pere Comas Casanova, Carlos Ruiz Martínez, Alberto Delgado-Iribarren, Berta Alonso-González, Isabel Moreno-Parra, Teresa Gómez-Ballesteros, Araceli Menéndez, Jose Manuel Añón, Ruth Jorge García, Jonathan Cámara Fernández, Miguel Górgolas Hernández-Mora, Itziar Diego Yagüe, Miriam Latorre-Millán, Covadonga Morcate Fernández, M. Río-García, Elisabet Lerma-Chippirraz, Carmen Yllera Gutiérrez, Francesc Albertí, Eva Flores, Carmen R. Uña Orejón, Patricio González-Pizarro, Neila Rodriguez-Roca, Miguel Fernández-Huerta, Inés Ferrer Ortiz, María José Blanco Vidal, Juan Pablo Avilés, Alicia Lorenzo Hernández, Mireia Puig Campmany, José Bravo-Ferrer, Gonzalo Martínez-Alés, Pablo Marguenda Contreras, M. Sánchez, Antonio García Pardo, Yolanda Meije, Francisco Tejerina, Carolina Hernández Carballo, Victoria Moreno, Daniel Laorden-Escudero, Ana Barrios Blandino, Alexia Costanza Espiño Álvarez, Ana Milagro Beamonte, Jerónimo Pachón, S San José-Villar, Marta Morando, María del Carmen Navarro Sáez, Rodolfo Álvarez-Sala Walther, Jon Ugalde Espiñeira, Fernando De la Calle Prieto, Nuria Fernández, Iván Pelegrín Senent, Alba Rueda López, Cristina Schüffelmann, Marcelino Hayek Peraza, Laura Labajo-Montero, Angel Robles Marhuenda, Pilar Durán, Ana Esteban-Romero, María Rosa Oltra Sempere, Ana Cosmen Sánchez, Alex Smithson Amat, Margarita Ramírez-Schacke, Marco Antonio Sempere Alcocer, Paloma Carrera-Vázquez, M Miarons, Teresa García Delange, Amelia Rodriguez-Mariblanca, Eva Talavera García, Roberto Vates Gómez, Óscar Sanz Peláez, José María Muñoz-Ramón, José Luis García Fogeda, Isabel Arroyo-Rico, Verónica Cano Llorente, Fernando González-Romo, Alberto Alonso-Babarro, Fátima Brañas, Fabricio Iannuccelli, Pilar Álvarez Padín, Luis Metola Sacristán, Vicente Boix, Víctor Hontañón, Juan Berenguer, José Luís Del Pozo León, Patricia Sorní Moreno, Maria Isabel Torres, Rafael Mican Rivera, Amparo Blasco Claramunt, Carmen Ardanuy, Aychel Elena Roura Piloto, María Ángeles Molina, Isabel Asschert Agüero, Julía Alvárez del Vayo, Consuelo García-Sánchez, Begoña Reche-Martínez, Guillermo Cuervo, Carlos Iniesta, María Antonia Gómez-Mendieta, Ana María Noblejas Mozo, Andres Bartrina-Tarrio, Carmen De la Higuera Arranz, Yeray Untoria Tabares, Andrés Enrique Suárez-Plaza, Jesús Frías, Paloma López-Arévalo, Irene María Llorente-Cortijo, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), and Fundación SEIMC-GESIDA
- Subjects
Male ,Prognostic variable ,medicine.medical_specialty ,Databases, Factual ,Coronavirus disease 2019 (COVID-19) ,030204 cardiovascular system & hematology ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Humans ,Medicine ,030212 general & internal medicine ,Aged ,Retrospective Studies ,Models, Statistical ,SARS-CoV-2 ,business.industry ,Mortality rate ,COVID-19 ,Retrospective cohort study ,Articles ,Middle Aged ,Prognosis ,medicine.disease ,Phenotype ,Hospitals ,Hospitalization ,Logistic Models ,Infectious Diseases ,Spain ,Cohort ,Female ,Lymphocytopenia ,business ,Cohort study - Abstract
REIPI-SEIMC COVID-19 group and COVID@HULP group., [Background] The clinical presentation of COVID-19 in patients admitted to hospital is heterogeneous. We aimed to determine whether clinical phenotypes of patients with COVID-19 can be derived from clinical data, to assess the reproducibility of these phenotypes and correlation with prognosis, and to derive and validate a simplified probabilistic model for phenotype assignment. Phenotype identification was not primarily intended as a predictive tool for mortality., [Methods] In this study, we used data from two cohorts: the COVID-19@Spain cohort, a retrospective cohort including 4035 consecutive adult patients admitted to 127 hospitals in Spain with COVID-19 between Feb 2 and March 17, 2020, and the COVID-19@HULP cohort, including 2226 consecutive adult patients admitted to a teaching hospital in Madrid between Feb 25 and April 19, 2020. The COVID-19@Spain cohort was divided into a derivation cohort, comprising 2667 randomly selected patients, and an internal validation cohort, comprising the remaining 1368 patients. The COVID-19@HULP cohort was used as an external validation cohort. A probabilistic model for phenotype assignment was derived in the derivation cohort using multinomial logistic regression and validated in the internal validation cohort. The model was also applied to the external validation cohort. 30-day mortality and other prognostic variables were assessed in the derived phenotypes and in the phenotypes assigned by the probabilistic model., [Findings] Three distinct phenotypes were derived in the derivation cohort (n=2667)—phenotype A (516 [19%] patients), phenotype B (1955 [73%]) and phenotype C (196 [7%])—and reproduced in the internal validation cohort (n=1368)—phenotype A (233 [17%] patients), phenotype B (1019 [74%]), and phenotype C (116 [8%]). Patients with phenotype A were younger, were less frequently male, had mild viral symptoms, and had normal inflammatory parameters. Patients with phenotype B included more patients with obesity, lymphocytopenia, and moderately elevated inflammatory parameters. Patients with phenotype C included older patients with more comorbidities and even higher inflammatory parameters than phenotype B. We developed a simplified probabilistic model (validated in the internal validation cohort) for phenotype assignment, including 16 variables. In the derivation cohort, 30-day mortality rates were 2·5% (95% CI 1·4–4·3) for patients with phenotype A, 30·5% (28·5–32·6) for patients with phenotype B, and 60·7% (53·7–67·2) for patients with phenotype C (log-rank test p, [Interpretation] Patients admitted to hospital with COVID-19 can be classified into three phenotypes that correlate with mortality. We developed and validated a simplified tool for the probabilistic assignment of patients into phenotypes. These results might help to better classify patients for clinical management, but the pathophysiological mechanisms of the phenotypes must be investigated., [Funding] Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, and Fundación SEIMC/GeSIDA., Funding: Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, and Fundación SEIMC/GeSIDA.
- Published
- 2021
29. Modulation of Monocyte Activation and Function during Direct Antiviral Agent Treatment in Patients Coinfected with HIV and Hepatitis C Virus
- Author
-
Yusnelkis Milanés-Guisado, Maria Trujillo-Rodriguez, Ana I. Alvarez-Rios, Luis F. López-Cortés, Alicia Gutierrez-Valencia, M. Reyes Jimenez-Leon, Ezequiel Ruiz-Mateos, Pompeyo Viciana, Nuria Espinosa, Cristina Roca-Oporto, Rebeca S. de Pablo-Bernal, Ana Serna-Gallego, Laura Tarancon-Diez, Instituto de Salud Carlos III, Red Española de Investigación en SIDA, European Commission, and Junta de Andalucía
- Subjects
Lipopolysaccharide ,cell-associated DNA ,Cell-associated DNA: Inflammation ,HIV Infections ,Hepacivirus ,CD49d ,medicine.disease_cause ,Monocytes ,chemistry.chemical_compound ,0302 clinical medicine ,CX3CR1 ,Pharmacology (medical) ,0303 health sciences ,biology ,medicine.diagnostic_test ,Coinfection ,virus diseases ,Hepatitis C ,Infectious Diseases ,medicine.anatomical_structure ,polyfunctionality ,monocyte ,HCV ,030211 gastroenterology & hepatology ,Tumor necrosis factor alpha ,Hepatitis C virus ,Activation ,Antiviral Agents ,Flow cytometry ,03 medical and health sciences ,medicine ,Humans ,030304 developmental biology ,Reservoir ,Pharmacology ,CD40 ,business.industry ,Monocyte ,HIV ,DAAs ,Hepatitis C, Chronic ,Monocyte: Polyfunctionality ,chemistry ,inflammation ,Polyfunctionality [Monocyte] ,Immunology ,biology.protein ,Inflammation [Cell-associated DNA] ,business - Abstract
The activation phenotypes and functional changes in monocyte subsets during hepatitis C virus (HCV) elimination in HIV/HCV-coinfected patients were evaluated. Twenty-two HIV/HCV-coinfected patients on suppressive combination antiretroviral treatment (cART) achieving HCV elimination after direct-acting antiviral (DAA) therapy and 10 HIV-monoinfected patients were included. The activation phenotype (10 markers) and polyfunctionality (intracellular interleukin-1α [IL-1α], IL-1β, IL-6, IL-8, tumor necrosis factor alpha [TNF-α], and IL-10 production) in three monocyte subsets (classical, intermediate, and nonclassical) were evaluated by flow cytometry before and at the end of treatment. Cell-associated HIV DNA levels were assayed by droplet digital PCR. After HCV clearance, there was a significant increase in classical monocyte and decreases in intermediate and nonclassical monocyte levels. The levels of the activation markers CD49d, CD40, and CX3CR1 were decreased after treatment in the monocyte subsets, reaching the levels in HIV-monoinfected patients. After lipopolysaccharide (LPS) stimulation, although polyfunctionality significantly decreased in intermediate and nonclassical monocytes, some combinations, such as the IL-1α− (IL-1α-negative) IL-1β− IL-6+ (IL-6-producing) IL-8− TNF-α− IL-10− combination, were remarkably increased at the end of treatment compared to the control group. Cell-associated HIV DNA levels correlated with activation markers before but not after treatment. HCV clearance after DAA treatment in patients on cART exerts an anti-inflammatory profile on monocyte subsets, activation phenotypes, and polyfunctionality. However, there is not a complete normalization compared with HIV-monoinfected patients., This work was supported by the Instituto de Salud Carlos III (research contracts CPII014/00025 to E.R.-M., CP19/00159 to A.G.-V., FI17/00186 to M.R.J.-L., and FI14/00431 to L.T.-D. and research projects PI16/00684 and PI19/01127 to E.R.-M.) and the Red Temática de Investigación Cooperativa en SIDA (RD16/0025/0020 and RD16/0025/0019), which is included in the Acción Estratégica en Salud, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica, 2008 to 2011 and 2013 to 2016, Instituto de Salud Carlos III, Fondos FEDER. E.R.-M. was supported by the Consejería de Salud y Bienestar Social of the Junta de Andalucía through the Nicolás Monardes program (C-0032/17).
- Published
- 2020
30. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy
- Author
-
Maria Velasco Arribas, Montserrat Sanmartí Vilamala, Nuria Espinosa, Carlos Iniesta, Inés Suárez-García, Alfonso Cabello-Ubeda, Asuncion Diaz, INMA JARRIN, Adrian Curran, Elena Vanessa Martínez Sánchez, Jorge N. García Pérez, DAVID DALMAU, Jose Maria García de Lomas Guerrero, Rocio Montejano Sanchez, Jose Antonio Perez-Molina, Marta Montero, Santiago Moreno, Alexy Inciarte, Anna Rull, Maria De Lagarde, Alfonso Del Arco Jiménez, Luis Fernando Lopez.Cortes, Rafael Mican, Elisa De Lazzari, Vicens Diaz-Brito, and Jose Arribas
- Subjects
Male ,Human immunodeficiency virus (HIV) ,HIV Infections ,medicine.disease_cause ,Severity of Illness Index ,01 natural sciences ,Cohort Studies ,0302 clinical medicine ,COVID-19 Testing ,Abacavir ,Antiretroviral Therapy, Highly Active ,Emtricitabine ,030212 general & internal medicine ,Original Research ,Reverse Transcriptase Polymerase Chain Reaction ,Incidence (epidemiology) ,Incidence ,Lamivudine ,virus diseases ,General Medicine ,Middle Aged ,Hospitalization ,Drug Combinations ,Intensive Care Units ,Female ,Coronavirus Infections ,medicine.drug ,Cohort study ,Adult ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,MEDLINE ,Lower risk ,Tenofovir alafenamide ,03 medical and health sciences ,Betacoronavirus ,Internal medicine ,Severity of illness ,Internal Medicine ,medicine ,Humans ,0101 mathematics ,Tenofovir ,Pandemics ,Aged ,business.industry ,Clinical Laboratory Techniques ,SARS-CoV-2 ,Adenine ,010102 general mathematics ,COVID-19 ,Antiretroviral therapy ,Dideoxynucleosides ,Spain ,business - Abstract
This study describes the incidence and severity of COVID-19 among 77 590 HIV-positive patients receiving antiretroviral therapy (ART). These findings warrant further investigation of HIV ART in HIV preexposure prophylaxis studies and randomized trials among persons without HIV., Visual Abstract. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving ART This study describes the incidence and severity of COVID-19 among 77 590 HIV-positive patients receiving antiretroviral therapy (ART). These findings warrant further investigation of HIV ART in HIV preexposure prophylaxis studies and randomized trials among persons without HIV. Visual Abstract. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving ART This study describes the incidence and severity of COVID-19 among 77 590 HIV-positive patients receiving antiretroviral therapy (ART). These findings warrant further investigation of HIV ART in HIV preexposure prophylaxis studies and randomized trials among persons without HIV., Background: The incidence and severity of coronavirus disease 2019 (COVID-19) among HIV-positive persons receiving antiretroviral therapy (ART) have not been characterized in large populations. Objective: To describe the incidence and severity of COVID-19 by nucleos(t)ide reverse transcriptase inhibitor (NRTI) use among HIV-positive persons receiving ART. Design: Cohort study. Setting: HIV clinics in 60 Spanish hospitals between 1 February and 15 April 2020. Participants: 77 590 HIV-positive persons receiving ART. Measurements: Estimated risks (cumulative incidences) per 10 000 persons and 95% CIs for polymerase chain reaction–confirmed COVID-19 diagnosis, hospitalization, intensive care unit (ICU) admission, and death. Risk and 95% CIs for COVID-19 diagnosis and hospital admission by use of the NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafenamide (TAF)/FTC, abacavir (ABC)/lamivudine (3TC), and others were estimated through Poisson regression models. Results: Of 77 590 HIV-positive persons receiving ART, 236 were diagnosed with COVID-19, 151 were hospitalized, 15 were admitted to the ICU, and 20 died. The risks for COVID-19 diagnosis and hospitalization were greater in men and persons older than 70 years. The risk for COVID-19 hospitalization was 20.3 (95% CI, 15.2 to 26.7) among patients receiving TAF/FTC, 10.5 (CI, 5.6 to 17.9) among those receiving TDF/FTC, 23.4 (CI, 17.2 to 31.1) among those receiving ABC/3TC, and 20.0 (CI, 14.2 to 27.3) for those receiving other regimens. The corresponding risks for COVID-19 diagnosis were 39.1 (CI, 31.8 to 47.6), 16.9 (CI, 10.5 to 25.9), 28.3 (CI, 21.5 to 36.7), and 29.7 (CI, 22.6 to 38.4), respectively. No patient receiving TDF/FTC was admitted to the ICU or died. Limitation: Residual confounding by comorbid conditions cannot be completely excluded. Conclusion: HIV-positive patients receiving TDF/FTC have a lower risk for COVID-19 and related hospitalization than those receiving other therapies. These findings warrant further investigation in HIV preexposure prophylaxis studies and randomized trials in persons without HIV. Primary Funding Source: Instituto de Salud Carlos III and National Institutes of Health.
- Published
- 2020
31. Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study
- Author
-
Montserrat Sanmartí Vilamala, Nuria Espinosa, Carlos Iniesta, Inés Suárez-García, Alfonso Cabello-Ubeda, OSKAR AYERDI, INMA JARRIN, Esther Rodríguez-Gallego, Adrian Curran, Roberto Muga, Livia Giner, EVA POVEDA, DAVID DALMAU, Anaïs Corma-Gómez, Montserrat Vargas Laguna, Antonio Rivero Román, Juan González-García, Iñigo Sagastagoitia, Mar Vera, Marta Rava, ALICIA GONZALEZ-BAEZA, Eduardo Malmierca Corral, Maria Jose Amengual, Jose Maria García de Lomas Guerrero, MARIA REMEDIOS ALEMAN VALLS, Rocio Montejano Sanchez, Javier Martínez-Sanz, Chiara Fanciulli, Alejandro Gonzalez-Serna, Esperanza Merino de Lucas, Anna Rull, PATRICIA GONZALEZ-RUANO, Cristina Moreno Prieto, Alfonso Del Arco Jiménez, Luis Fernando Lopez.Cortes, Alexandre Pérez González, Rafael Mican, Félix Gutiérrez, Mª José Alcaraz, David Rial Crestelo, Eulalia Valle-Garay, Marta Fernández-González, Azucena Bautista Hernández, Víctor Hontañón Antoñana, and JOSE ALBERTO GARCIA GOMEZ
- Subjects
Microbiology (medical) ,Adult ,medicine.medical_specialty ,Anti-HIV Agents ,HIV Infections ,Gastroenterology ,Tenofovir alafenamide ,chemistry.chemical_compound ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Viral suppression ,Adverse effect ,Pharmacology ,Creatinine ,Acquired Immunodeficiency Syndrome ,business.industry ,Viral Load ,CD4 Lymphocyte Count ,Regimen ,Infectious Diseases ,chemistry ,Anti-Retroviral Agents ,Cohort ,business ,Viral load ,Cohort study - Abstract
ObjectivesWe compared 48 week effectiveness and safety of first-line antiretroviral regimens.MethodsWe analysed HIV treatment-naive adults from the Cohort of the Spanish HIV/AIDS Research Network (CoRIS) starting the most commonly used antiretroviral regimens from 2014 to 2018. We used multivariable regression models to assess the impact of initial regimen on: (i) viral suppression (VS) (viral load 0.4 and >1); (iv) CD4 percentage normalization (>29%); (v) multiple T-cell marker recovery (MTMR: CD4 > 500 cells/mm3 plus CD4 percentage >29% plus CD4/CD8 > 1); (vi) lipid, creatinine and transaminase changes; and (vii) discontinuations due to adverse events (AE).ResultsAmong 3945 individuals analysed, the most frequently prescribed regimens were ABC/3TC/DTG (34.0%), TAF/FTC/EVG/CBT (17.2%), TDF/FTC + DTG (11.9%), TDF/FTC/EVG/CBT (11.7%), TDF/FTC/RPV (11.5%), TDF/FTC + bDRV (8.3%) and TDF/FTC + RAL (5.3%). At 48 weeks, 89.7% of individuals achieved VS with no significant differences by initial regimen. CD4 mean increase was 257.8 (249.3; 266.2) cells/mm3, and it was lower with TAF/FTC/EVG/CBT and TDF/FTC/RPV compared with ABC/3TC/DTG. CD4 percentage normalization was less likely with TAF/FTC/EVG/CBT, and MTMR was less likely with TAF/FTC/EVG/CBT and TDF/FTC + RAL. The proportion of discontinuations due to AE was higher with TDF/FTC + bDRV (9.7%), followed by TDF/FTC/EVG/CBT (9.5%) and TDF/FTC + DTG (7.9%). Compared with ABC/3TC/DTG, cholesterol and LDL mean increases were higher with TAF/FTC/EVG/CBT and lower with TDF/FTC + DTG, TDF/FTC/RPV and TDF/FTC + RAL. Higher mean increases in triglycerides were significantly associated with TAF/FTC/EVG/CBT. Regimens containing DTG showed higher creatinine increases.ConclusionsThe significantly greater immunological response and safety of some combinations may be useful for making decisions when initiating treatment.
- Published
- 2020
32. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study
- Author
-
Montserrat Sanmartí Vilamala, Nuria Espinosa, Carlos Iniesta, Inés Suárez-García, Federico Pulido, Alfonso Cabello-Ubeda, OSKAR AYERDI, Víctor Asensi Álvarez, INMA JARRIN, Andrés Navarro Ruiz, Ignacio De Los Santos Gil, Esther Rodríguez-Gallego, Pedro Herranz, Paloma Gijon, Mar Masiá, Adrian Curran, Roberto Muga, Mariona Xercavins, Livia Giner, LUZ MARTÍN CARBONERO, EVA POVEDA, DAVID DALMAU, Anaïs Corma-Gómez, Montserrat Vargas Laguna, Eulalia Valencia, Juan González-García, Mar Vera, ALICIA GONZALEZ-BAEZA, Eduardo Malmierca Corral, Maria Jose Amengual, Francisco Arnalich Fernandez, Jose Maria García de Lomas Guerrero, MARIA REMEDIOS ALEMAN VALLS, Rocio Montejano Sanchez, Javier Martínez-Sanz, Maria José Mellado Peña, Laura Perez-Martinez, Xavier Barber, Chiara Fanciulli, Sergio Serrano-Villar, Alejandro Gonzalez-Serna, Sergio Padilla, Esperanza Merino de Lucas, Anna Rull, PATRICIA GONZALEZ-RUANO, Cristina Moreno Prieto, Alfonso Del Arco Jiménez, Luis Fernando Lopez.Cortes, Alexandre Pérez González, Rafael Mican, Rafael Rubio García, Félix Gutiérrez, Marta Ruiz-Algueró, Mª José Alcaraz, David Rial Crestelo, Eulalia Valle-Garay, Marta Fernández-González, Asuncion Hernando, Víctor Hontañón Antoñana, Jose Arribas, JOSE ALBERTO GARCIA GOMEZ, Instituto de Salud Carlos III - ISCIII, European Regional Development Fund (ERDF/FEDER), UAM. Departamento de Medicina, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Instituto de Salud Carlos III, European Commission, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (ISS-FJD), and European Regional Development Fund
- Subjects
0301 basic medicine ,Male ,Enfermedad transmisible ,HIV Infections ,Quinolones ,Gastroenterology ,Estudio de caso ,0302 clinical medicine ,Medicine ,Emtricitabine ,Pharmacology (medical) ,030212 general & internal medicine ,Darunavir ,Elvitegravir ,Cobicistat ,Serodiagnóstico del SIDA ,Middle Aged ,Viral Load ,Treatment Outcome ,Tolerability ,Molecular Medicine ,Cohort studies ,Drug Therapy, Combination ,Female ,Viral load ,medicine.drug ,lcsh:Immunologic diseases. Allergy ,Adult ,medicine.medical_specialty ,Medicina ,Anti-HIV Agents ,Sida ,030106 microbiology ,Tenofovir alafenamide ,03 medical and health sciences ,Highly active antiretroviral therapy ,Virology ,Internal medicine ,Humans ,Tenofovir ,business.industry ,Research ,HIV infection ,Regimen ,Spain ,HIV-1 ,business ,lcsh:RC581-607 - Abstract
© The Author(s) 2020., [Background]: The aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS)., [Methods]: Treatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014–2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL), [Results]: We included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL, [Conclusions]: EVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads., The RIS cohort (CoRIS) is supported by the Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida (RD06/006, RD12/0017/0018 and RD16/0002/0006) as part of the Plan Nacional I+D+i and cofnanced by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER)”.
- Published
- 2020
33. Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?
- Author
-
Yusnelkis Milanés-Guisado, Alicia Gutierrez-Valencia, Luis F. López-Cortés, Antonio Rivero, Ezequiel Ruiz-Mateos, Maria Trujillo-Rodriguez, Nuria Espinosa, Cristina Roca-Oporto, Pompeyo Viciana, Juan Manuel Muñoz-Pichardo, Red Española de Investigación en SIDA, Instituto de Salud Carlos III, and European Commission
- Subjects
Adult ,Male ,Microbiology (medical) ,CD4-CD8 Ratio ,Integrase inhibitor ,Non-nucleoside reverse transcriptase inhibitors ,Brief pain inventory ,Anti-retroviral agents ,Pharmacology ,Integrase ,hiv infections ,Nucleoside Reverse Transcriptase Inhibitor ,Transfer technique ,Endopeptidases ,Integrase inhibitors ,Humans ,Medicine ,Pharmacology (medical) ,Protease inhibitor (pharmacology) ,HIV Integrase Inhibitors ,t-lymphocytes ,Retrospective Studies ,cd4 count determination procedure ,Viral load result ,biology ,business.industry ,Repeated measures design ,Nucleosides ,HIV Protease Inhibitors ,Middle Aged ,Viral Load ,Immune reconstitution ,Reverse transcriptase ,humanities ,Peptide hydrolases ,CD4 Lymphocyte Count ,Infectious Diseases ,Blood hiv rna ,biology.protein ,Reverse Transcriptase Inhibitors ,Female ,Ncleoside reverse transcriptase inhibitors ,business ,Viral load ,CD8 - Abstract
[Objectives] To analyse whether integrase inhibitor (InSTI)-based regimens achieve better immunological recovery than NNRTI- or boosted PI (bPI)-based regimens as initial ART., [Methods] In a retrospective analysis, we selected patients who initiated ART with two NRTIs plus an InSTI, an NNRTI or a bPI and maintained both the same ‘third drug’ and an HIV-RNA, [Results] Of the 836 patients included, 208, 481 and 147 initiated with InSTI, NNRTI and bPI, respectively. For CD4+, %CD4+ and CD4+/CD8+ two main slopes were identified: from month 0 to month 6, with the highest increments; and from month 6 to month 24, with smaller increases every semester. Although the patients on InSTI achieved undetectable viral load faster, for CD4+ and %CD4+ there were no differences in the slopes of change according to the third drug either for the first phase (P=0.137 and P=0.393, respectively) or from month 6 onwards (P=0.834 and P=0.159, respectively). The increase in CD4+/CD8+ was slightly higher for bPI compared with InSTI (difference of 0.0119, 95% CI 0.0020–0.0205; P=0.018), but clinically negligible. From month 6 onwards, no differences were found between treatment groups (P=0.176)., [Conclusions] Immune restoration measured as CD4+ count, %CD4+ and CD4+/CD8+ increases was independent of the third antiretroviral drug class used when given with two NRTIs., This work was supported by Red de Investigación en SIDA (RD16/0025/0020-ISCIII-FEDER) and Instituto de Salud Carlos III and Proyectos de investigación en salud (AES 2018) (exp. PI18/01298).
- Published
- 2020
34. Physicians' opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain
- Author
-
Montserrat Sanmartí Vilamala, Nuria Espinosa, Carlos Iniesta, Inés Suárez-García, Miriam Estebanez, Alfonso Cabello-Ubeda, INMA JARRIN, Ignacio De Los Santos Gil, Esther Rodríguez-Gallego, Mar Masiá, Adrian Curran, Roberto Muga, Livia Giner, Ignacio Pérez Valero, EVA POVEDA, DAVID DALMAU, Anaïs Corma-Gómez, Montserrat Vargas Laguna, Juan González-García, Mar Vera, ALICIA GONZALEZ-BAEZA, Eduardo Malmierca Corral, Maria Jose Amengual, Jose Maria García de Lomas Guerrero, Vicente Boix, MARIA REMEDIOS ALEMAN VALLS, Adelina Gimeno Gascon, Rocio Montejano Sanchez, Javier Martínez-Sanz, Chiara Fanciulli, Alejandro Gonzalez-Serna, Esperanza Merino de Lucas, Anna Rull, PATRICIA GONZALEZ-RUANO, Cristina Moreno Prieto, Alfonso Del Arco Jiménez, Luis Fernando Lopez.Cortes, Alexandre Pérez González, Rafael Mican, Marta Ruiz-Algueró, Mª José Alcaraz, David Rial Crestelo, Eulalia Valle-Garay, Marta Fernández-González, Víctor Hontañón Antoñana, Jose Arribas, Mª Jesus Perez Elias, and JOSE ALBERTO GARCIA GOMEZ
- Subjects
0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Attitude of Health Personnel ,Sida ,España ,MEDLINE ,Enfermedad transmisible ,HIV Infections ,Computer-assisted web interviewing ,03 medical and health sciences ,0302 clinical medicine ,Acquired immunodeficiency syndrome (AIDS) ,Physicians ,Surveys and Questionnaires ,Antirretrovirales ,Drugs, Generic ,Humans ,Medicine ,Pharmacology (medical) ,030212 general & internal medicine ,Adverse effect ,Pharmacology ,biology ,business.industry ,virus diseases ,Serodiagnóstico del SIDA ,biology.organism_classification ,medicine.disease ,030112 virology ,Regimen ,Infectious Diseases ,Spain ,Family medicine ,Pill ,Cohort ,business ,Tablets - Abstract
ObjectivesTo assess the attitudes and opinions about generic antiretroviral drugs (ARVs) and single-tablet regimen (STR) de-simplification among physicians prescribing HIV treatment in the cohort of the Spanish HIV/AIDS Research Network (CoRIS).MethodsAn online questionnaire with 27 structured questions was sent to all physicians (n = 199) who prescribed ARVs among the 45 centres participating in the cohort.ResultsA total of 169 (84.9%) physicians answered the questionnaire. Only 4.1% of the physicians would never prescribe generic ARVs, but 53.3% would not prescribe them if the number of pills per day increased and 89.3% would not prescribe them if the number of doses per day increased. However, 84.0% of the physicians agreed to prescribe generic ARVs if doing so would decrease costs for the public healthcare system. The percentages of physicians stating that generic ARVs (compared with branded ones) would be associated with worse adherence, more adverse effects or more probability of virological failure, provided that the number of pills and doses per day would not change, were low: 0.6%, 7.7% and 3.6%, respectively. However, these percentages were much higher if the generic ARV entailed breaking an STR: 63.9%, 18.9% and 42.0%, respectively. Most physicians stated that they needed more information about the effectiveness and safety of generic ARVs and the price difference compared with their branded equivalents.ConclusionsAlthough most physicians were confident about prescribing generic ARVs, the majority had strong concerns about de-simplifying STR, and they also needed more information about generic drugs.
- Published
- 2020
35. Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients
- Author
-
José Luis Santiago Blanco, José L. Casado, Rocío Montejano, Nuria Espinosa, Jorge Vergas, Rosario Palacios, Marta Montero, Pilar Vizcarra, María José Galindo, Miguel García Deltoro, Alberto Diaz de Santiago, Juan Carlos López, Álvaro Mena, Eugenia Negredo, and Alfonso Cabello
- Subjects
Male ,Resistance ,Human immunodeficiency virus (HIV) ,HIV Infections ,darunavir ,Comorbidity ,Hepacivirus ,030312 virology ,medicine.disease_cause ,Simplification ,0302 clinical medicine ,Hiv infected patients ,Pharmacology (medical) ,030212 general & internal medicine ,Darunavir ,Aged, 80 and over ,0303 health sciences ,Coinfection ,switching ,Middle Aged ,Viral Load ,Hepatitis C ,Treatment Outcome ,Infectious Diseases ,Female ,raltegravir ,medicine.drug ,Adult ,medicine.medical_specialty ,Dual therapy ,Anti-HIV Agents ,Dermatology ,Treatment experienced ,resistance ,03 medical and health sciences ,Raltegravir Potassium ,Internal medicine ,medicine ,Humans ,HIV Integrase Inhibitors ,Aged ,Retrospective Studies ,Toxicity ,business.industry ,Public Health, Environmental and Occupational Health ,simplification ,toxicity ,HIV Protease Inhibitors ,Raltegravir ,Spain ,Switching ,business - Abstract
BIRDi study group., The use of two potent, well-tolerated, drugs could permit the maintenance of virologic suppression even in heavily pretreated people living with HIV. In this retrospective, multicenter, simplification study (NCT03348449), we included those patients with virologic suppression who switched to raltegravir (RAL) plus boosted darunavir (b/DRV). Overall, 345 patients (75 females, 25%) were included. Patients were largely pretreated (mean, 9.4 regimens), suppressed for a median of 41.1 months. Fifty patients had ≥1 mutation against DRV. At 96 weeks, the efficacy by intention-to-treat analysis (snapshot) was 73% (95%CI, 68.4–77.8%), but 97.1% (95%CI, 95.4–98.9) excluding changes due to non-virologic reasons, and virologic failure was rare (0.9%; 95%CI, 0.1–1.2%). Median CD4/CD8 ratio increased from 0.59 to 0.62 (p
- Published
- 2020
36. Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy
- Author
-
Rocío Montejano, Nuria Espinosa, José L. Blanco, Eugenia Negredo, José L. Casado, Pilar Vizcarra, and MSD
- Subjects
0301 basic medicine ,Oncology ,Male ,Time Factors ,Sustained Virologic Response ,Resistance ,Human immunodeficiency virus (HIV) ,HIV Infections ,medicine.disease_cause ,Simplification ,0302 clinical medicine ,030212 general & internal medicine ,Treatment Failure ,Darunavir ,Drug Substitution ,General Medicine ,Middle Aged ,Drug Combinations ,Infectious Diseases ,Drug Therapy, Combination ,Female ,medicine.drug ,Microbiology (medical) ,Adult ,medicine.medical_specialty ,Dual therapy ,Genotype ,030106 microbiology ,CD4-CD8 Ratio ,Microbial Sensitivity Tests ,03 medical and health sciences ,Young Adult ,Internal medicine ,Raltegravir Potassium ,Drug Resistance, Viral ,medicine ,Humans ,Protease inhibitor (pharmacology) ,HIV Integrase Inhibitors ,Aged ,Retrospective Studies ,Ritonavir ,General Immunology and Microbiology ,business.industry ,HIV Protease Inhibitors ,Raltegravir ,Mutation ,Switching ,HIV-1 ,Cobicistat ,business - Abstract
[Background]: Little is known about the impact of baseline resistance-associated mutations (RAMs) on the outcomes of alternative therapeutic strategies such as dual regimens. We assessed the efficacy of boosted darunavir plus raltegravir (DRV + RAL) dual regimen as a simplification strategy in virologically suppressed patients with protease inhibitors RAMs., [Methods]: Retrospective, multicentre study on the evolution of 228 heavily pretreated patients who switched to boosted DRV + RAL according to genotypic sensitivity score (GSS). Patients were classified as full susceptible (GSS = 2; n = 177), or with reduced darunavir susceptibility (GSS < 2; n = 51)., [Results]: Median (range) number of prior antiretroviral regimens was 9 (6–14), with a median (range) of 2 (1–3), 4 (3–6), and 5 (2–9) major mutations to non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, and protease inhibitors, respectively. The median time of virological suppression before simplification was 49 months (IQR 39.8–63.5). Patients with reduced darunavir GSS showed a higher number of protease inhibitors-RAMs (9.3 vs 4.5, p, [Conclusions]: Treatment simplification to a dual regimen of boosted DRV + RAL after long-term virological suppression was not associated with a high risk of treatment failure, even in patients harbouring protease inhibitors-resistant HIV infection., This study was supported by the MSD Investigator-Initiated Studies Program (MISP) under grant number 57180.
- Published
- 2020
37. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain
- Author
-
Montserrat Sanmartí Vilamala, Nuria Espinosa, Inés Suárez-García, Federico Pulido, Eva Calabuig, Alfonso Cabello-Ubeda, Berta Pernas, Víctor Asensi Álvarez, INMA JARRIN, Andrés Navarro Ruiz, Ignacio De Los Santos Gil, Esther Rodríguez-Gallego, Pedro Herranz, Juan A. Pineda, Paloma Gijon, Mar Masiá, Roberto Muga, Mariona Xercavins, Livia Giner, LUZ MARTÍN CARBONERO, Ignacio Pérez Valero, EVA POVEDA, DAVID DALMAU, Montserrat Vargas Laguna, Juan González-García, Mar Vera, ALICIA GONZALEZ-BAEZA, José A. Oteo, Eduardo Malmierca Corral, Maria Jose Amengual, Francisco Arnalich Fernandez, Jose Maria García de Lomas Guerrero, Vicente Boix, Rocio Montejano Sanchez, Maria José Mellado Peña, Xavier Barber, Marta Montero, Sergio Padilla, Esperanza Merino de Lucas, Anna Rull, PATRICIA GONZALEZ-RUANO, Rosa De Miguel Buckley, Mª Ángeles Muñoz-Fernández, Angeles Jaen, José Ignacio Bernardino, Cristina Moreno Prieto, Alfonso Del Arco Jiménez, Luis Fernando Lopez.Cortes, Rafael Mican, Rafael Rubio García, Félix Gutiérrez, Eulalia Valle-Garay, Marta Fernández-González, Juan Berenguer, Asuncion Hernando, Víctor Hontañón Antoñana, Jose Arribas, Mª Jesus Perez Elias, JOSE ALBERTO GARCIA GOMEZ, Instituto de Salud Carlos III, and European Commission
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Sida ,Enfermedad transmisible ,HIV Infections ,Practice guidelines ,Men who have sex with men ,03 medical and health sciences ,0302 clinical medicine ,Acquired immunodeficiency syndrome (AIDS) ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Syphilis ,Latent tuberculosis ,business.industry ,Health Policy ,Health care quality assurance ,virus diseases ,Hepatitis A ,Health care quality indicators ,Serodiagnóstico del SIDA ,Viral Load ,HIV infection ,medicine.disease ,Hepatitis B ,030112 virology ,Hepatitis C ,CD4 Lymphocyte Count ,Infectious Diseases ,Logistic Models ,Serology ,Spain ,Cohort ,Practice Guidelines as Topic ,Cohort studies ,Female ,Guideline Adherence ,business ,Viral load ,Atención a la salud ,Cohort study - Abstract
[Objectives]: The aim of this study was to evaluate adherence to the recommendations of the Spanish guidelines for the initial assessment of patients with HIV infection in the multicentre Cohort of the Spanish HIV/AIDS Network (CoRIS) during the years 2004–2017., [Methods]: We calculated the percentage of patients who had each of 11 clinical and analytical recommended examinations performed in their initial evaluation. We evaluated the factors associated with not performing each examination with multivariable logistic regression models., [Results]: We included 13 612 patients in the study. In the initial assessment, CD4 count and viral load were determined in more than 98.0% of the patients. Serologies for hepatitis A, B and C and syphilis were determined in 55.8%, 66.4%, 89.8% and 81.7% of the patients, respectively. Total cholesterol and creatinine were determined in 78.7% and 78.9% of the patients, respectively. The lowest proportions of examinations were observed for blood pressure, smoking status and latent tuberculosis screening, which were performed in 43.2%, 50.6% and 53.9% of the patients, respectively. Injecting drug users and heterosexual patients (compared to men who have sex with men) and patients with a lower educational level had a higher risk of having an incomplete initial assessment for a substantial number of examinations. Latent tuberculosis screening was less likely in patients with CD4 counts < 200 cells/µL., [Conclusions]: The initial assessment of HIV‐infected patients is suboptimal for the evaluation of cardiovascular risk, smoking status, screening of syphilis and viral hepatitis, and diagnosis of latent tuberculosis: adherence to the guidelines was low for these examinations., The RIS cohort (CoRIS) is supported by the Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida (RD06/006, RD12/ 0017/0018 and RD16/0002/0006) as part of the Plan Nacional I+D+i and cofinanced by ISCIII-Subdireccion General de Evaluacion and the Fondo Europeo de Desarrollo Regional (FEDER).
- Published
- 2019
38. Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions
- Author
-
Alicia Gutierrez-Valencia, Luis F. López-Cortés, Silvia Llaves-Flores, Pompeyo Viciana, Karin Neukam, Nuria Espinosa, Red Española de Investigación en SIDA, and Instituto de Salud Carlos III
- Subjects
Adult ,Male ,medicine.medical_specialty ,Hepatitis B virus ,030231 tropical medicine ,CD4-CD8 Ratio ,Immunization, Secondary ,HIV Infections ,medicine.disease_cause ,Immunocompromised Host ,03 medical and health sciences ,0302 clinical medicine ,CD4/CD8 ratio ,Interquartile range ,Antiretroviral Therapy, Highly Active ,Internal medicine ,Humans ,Medicine ,Hiv infected patients ,030212 general & internal medicine ,Immunization Schedule ,Retrospective Studies ,General Veterinary ,General Immunology and Microbiology ,Coinfection ,business.industry ,Vaccination ,Public Health, Environmental and Occupational Health ,virus diseases ,HIV ,Odds ratio ,Middle Aged ,Viral Load ,Hepatitis B ,medicine.disease ,Confidence interval ,digestive system diseases ,CD4 Lymphocyte Count ,Infectious Diseases ,ROC Curve ,Spain ,Molecular Medicine ,Female ,business - Abstract
[Background] HIV-infected patients are at risk of hepatitis B virus (HBV) coinfection, however, respond worse to HBV vaccination (HBV-V) than immunocompetent adults. This study aimed to determine the response to reinforced HBV-V in HIV-infected subjects under real-life conditions., [Methods] HIV-infected patients followed at a Spanish University Hospital who were seronegative for HBV and who received three double-doses (40 µL) of HBV-V at 0, 1 and 2 months were included. Response to HBV-V was defined as HBV surface antibody concentration of ≥10 IU/L 1–12 months after the last HBV-V dose., [Results] Of 332 patients included in the study, 256 (77.1%) showed response to HBV-V. Median (interquartile range) CD4+/CD8+ ratio among the responders was 0.75 (0.52–1.01) versus 0.61 (0.38–0.84) among the non-responders (p = 0.002). Independent predictors for HBV-V response were: female gender [adjusted odds ratio (AOR): 6.240; 95% confidence interval (95%CI): 1.954–19.925; p = 0.002]; non-smoking [AOR: 2.151; 95%CI: 1.243–3.721; p = 0.006]; a CD4+/CD8+ ratio ≥0.67 [AOR: 2.580; 95%CI: 1.209–5.505; p = 0.014] and baseline HIV-RNA ≤50 copies/mL [AOR: 2.049; 95%CI: 1.098–3.824; p = 0.024]., [Conclusion] Accelerated administration of three double-doses results in considerable high, however still suboptimal, response rates to HBV-V in HIV-infected patients in the clinical practice. A fourth dose should be considered., This work was partially funded by the Plan Nacional R+D+I and Red de Investigación en SIDA [grant number RD16/0025/0020-ISCIII-FEDER]. K.N. is the recipient of a Miguel Servet research grant [grant number CPII18/00033] from the Instituto de Salud Carlos III.
- Published
- 2019
39. Response to Hepatitis A Virus Vaccine in HIV-Infected Patients Within a Retrospective, Multicentric Cohort Facing Hepatitis A Outbreaks in the Clinical Practice
- Author
-
Alicia Gutierrez-Valencia, Marcial Delgado Fernández, Antonio Rivero-Juárez, Luis F. López-Cortés, Francisco Jiménez Oñate, Karin Neukam, Nuria Espinosa, Pompeyo Viciana, Silvia Llaves-Flores, and Jose Hernandez Quero
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,HIV Infections ,030312 virology ,Men who have sex with men ,Disease Outbreaks ,03 medical and health sciences ,Young Adult ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Seroconversion ,Aged ,Retrospective Studies ,0303 health sciences ,Hepatitis A Vaccines ,business.industry ,Coinfection ,Outbreak ,Hepatitis A ,virus diseases ,Odds ratio ,Middle Aged ,medicine.disease ,Confidence interval ,Vaccination ,Infectious Diseases ,Spain ,Cohort ,Female ,business - Abstract
Background] Various recent outbreaks of hepatitis A virus (HAV) have been described in men who have sex with men despite the availability of an effective vaccine. This study aimed to determine the current rates of seroconversion after receiving HAV vaccine (HAV-V) in HIV-infected patients under real-life conditions. Setting: Patients were selected from a Southern Spanish multicentric cohort of HIV-infected subjects. Methods: Retrospective analysis of all patients who received 2 doses (standard scheme) from April 2008 to May 2016 or from June 2016 to February 2018 facing an HAV outbreak with shortage of HAV-V, 1 single dose of HAV-V. Response to HAV-V was defined as positive anti-HAV IgG between 1 and 12 months after the last vaccination dose. Results: A total of 522 patients were included, mainly men who have sex with men (86.2%). In the standard-dose group, 303/343 [88.3%; 95% confidence interval (CI): 84.5 to 91.5] patients showed seroconversion as compared with 149/179 (83.2%; 95% CI: 76.9 to 88.4) of the single-dose group (P = 0.107). Undetectable baseline HIV-RNA (adjusted odds ratio: 4.86; 95% CI: 1.86 to 12.75; P = 0.001) and a CD4+ T-cell count ≥350/μL (adjusted odds ratio, 3.96; 95% CI: 1.26 to 12.49; P = 0.019) were independently associated with response to both regimens. A higher CD4/CD8+ ratio was also associated with response after a single dose. Conclusions: HIV-infected patients should be encouraged to undergo HAV-V with 2 standard doses 6 months apart; a single dose achieves a high rate of seroconversion in those patients with favorable response factors and may be enough to limit future outbreaks in case of HAV-V shortage until supply is reestablished., [Setting] Patients were selected from a Southern Spanish multicentric cohort of HIV-infected subjects., [Methods] Retrospective analysis of all patients who received 2 doses (standard scheme) from April 2008 to May 2016 or from June 2016 to February 2018 facing an HAV outbreak with shortage of HAV-V, 1 single dose of HAV-V. Response to HAV-V was defined as positive anti-HAV IgG between 1 and 12 months after the last vaccination dose., [Results] A total of 522 patients were included, mainly men who have sex with men (86.2%). In the standard-dose group, 303/343 [88.3%; 95% confidence interval (CI): 84.5 to 91.5] patients showed seroconversion as compared with 149/179 (83.2%; 95% CI: 76.9 to 88.4) of the single-dose group (P = 0.107). Undetectable baseline HIV-RNA (adjusted odds ratio: 4.86; 95% CI: 1.86 to 12.75; P = 0.001) and a CD4+ T-cell count ≥350/μL (adjusted odds ratio, 3.96; 95% CI: 1.26 to 12.49; P = 0.019) were independently associated with response to both regimens. A higher CD4/CD8+ ratio was also associated with response after a single dose., [Conclusions] HIV-infected patients should be encouraged to undergo HAV-V with 2 standard doses 6 months apart; a single dose achieves a high rate of seroconversion in those patients with favorable response factors and may be enough to limit future outbreaks in case of HAV-V shortage until supply is reestablished.
- Published
- 2019
40. Pseudo skin flash on VMAT in breast radiotherapy: Optimization of virtual bolus thickness and HU values
- Author
-
Nuria Jornet, Pablo Carrasco, María Lizondo, Anna Coral, Artur Latorre-Musoll, Montserrat Ribas, and Nuria Espinosa
- Subjects
Biophysics ,General Physics and Astronomy ,Patient positioning ,Breast Neoplasms ,Breast radiotherapy ,Computed tomography ,030218 nuclear medicine & medical imaging ,User-Computer Interface ,03 medical and health sciences ,Skin-flash tool ,0302 clinical medicine ,Bolus (medicine) ,Hounsfield scale ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Radiometry ,Radiation treatment planning ,Skin ,Volumetric arc therapy ,medicine.diagnostic_test ,business.industry ,Radiotherapy Planning, Computer-Assisted ,Isocenter ,General Medicine ,Volumetric modulated arc therapy ,030220 oncology & carcinogenesis ,Radiotherapy, Intensity-Modulated ,Tomography, X-Ray Computed ,business ,Nuclear medicine - Abstract
Purpose: Optimisation strategies for volumetric modulated arc therapy (VMAT) in most treatment planning systems for breast cancer do not account for patient positioning, breathing, or anatomical changes. To overcome this limitation, a pseudo-skin flash strategy using a virtual bolus has been proposed. Using this strategy, we determined optimal thickness and value of Hounsfield units (HU) assigned to the virtual bolus to ensure adequate CTV irradiation. Materials and methods: We modified the original computed tomography data (CT0) by adding combinations of thicknesses and densities of a virtual bolus on PTVs (CT') of seven bilateral breast cancer patients. Using a single optimization objective template, we obtained a VMAT plan on CT' and recalculated this on the CT0. Optimal CT' parameters were defined as those that minimized dose differences between CT' and CT0 plans regarding PTV and OAR dose-volume parameters. We studied bolus parameters regarding robustness by shifting the isocenter 5 and 10 mm in the breathing direction for each CT0 plan. Results: The minimal dosimetric impact was between - 400 and - 600 HU depending on bolus thickness. OARs doses were not significantly affected. Best robustness was found for - 500 HU and 15 mm bolus thickness against shifts of up to 10 mm in the breathing direction. Conclusion: Our results support a bolus thickness equal to the CTV-PTV margin plus 5 mm and a virtual bolus HU value around - 500 and - 400 depending on the bolus thickness chosen. These findings could play a useful role in maximising robustness and minimising the need for plan renormalization.
- Published
- 2019
41. High-risk human papilloma vrus testing improves diagnostic performance to predict moderate-to high-grade anal Intraepithelial neoplasia in human immunodeficiency virus-infected men who have xex with men in low-to-absent cytological abnormalities
- Author
-
Luis F. López-Cortés, Yusnelkis Milanés-Guisado, Ana Domínguez Castaño, Karin Neukam, Pompeyo Viciana, María Fontillón, Cesar Sotomayor, Nuria Espinosa, Instituto de Salud Carlos III, European Commission, and Red Española de Investigación en SIDA
- Subjects
Adult ,Male ,Microbiology (medical) ,medicine.medical_specialty ,Human papillomavirus ,Biopsy ,Cytodiagnosis ,HIV Infections ,Risk Assessment ,Sensitivity and Specificity ,Gastroenterology ,Men who have sex with men ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Cytology ,Odds Ratio ,medicine ,Humans ,030212 general & internal medicine ,Homosexuality, Male ,Papillomaviridae ,Neoplasm Staging ,Squamous intraepithelial lesions ,medicine.diagnostic_test ,Proctoscopes ,business.industry ,Papillomavirus Infections ,Disease Management ,Reproducibility of Results ,Anoscopy ,virus diseases ,Middle Aged ,Anus Neoplasms ,Anus ,Anal liquid-based cytology ,Confidence interval ,HIV-infected men who have sex with men ,Infectious Diseases ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Concomitant ,Cohort ,Neoplasm Grading ,Diagnostic performance ,business ,Algorithms ,Carcinoma in Situ - Abstract
[Background]: Screening methods for anal squamous intraepithelial lesions (SILs) are suboptimal. We aimed to determine the diagnostic performance of a composite endpoint comprising anal liquid-based cytology (aLBC) and high-risk human papillomavirus (HR-HPV) testing to predict histological high-grade SILs (hHSILs). [Methods]: From the SeVIHanal cohort, human immunodeficiency virus (HIV)-infected men who have sex with men (MSM) who had an aLBC with concomitant HR-HPV testing were included. hHSILs were determined by high-resolution anoscopy (HRA)-guided biopsy. [Results]: A total of 705 visits obtained from 426 patients were included. The prevalence of HR-HPV among aLBC results were 51.9% (133/215) normal, 87.9% (20/232) low-grade SILs (LSILs), and 90.9% (149/164) high-grade SILs; P (linear association) normal/noHR-HPV> (10%) and >LSIL/noHR-HPV> (4%). The prognostic values (95% confidence interval) for HR-HPV to predict hHSILs in normal cytology were positive predictive value (PPV), 29.3% (25.6%-33.3%); negative predictive value (NPV), 90.2% (82.8%-94.7%); sensitivity, 83% (69.2%-92.4%); and specificity, 44.1% (36.4%-51.9%). Corresponding figures for cytologic LSILs were PPV, 39.2% (37.4%-41.1%); NPV, 96.4% (78.9%-99.5%); sensitivity, 98.8% (93.3%-99.9%); and specificity, 17.9% (12.1%-24.9%). A positive interaction and a synergistic effect for the composite endpoint were observed (relative excess risk = 1.50, attributable proportion of histological results to interaction = 0.17, synergy index = 1.24). [Conclusions]: HRA should not be indicated in the setting of LSILs/noHR-HPV following aLBC-based screening. In contrast, HIV-infected MSM with normal aLBC/HR-HPV infection should be considered for HRA. Clinical Trials Registration: NCT03713229., This work was supported by the Plan Nacional R+D+I and the Red de Investigación en SIDA (grant RD16/0025/0020-ISCIII-FEDER). K. N. is the recipient of a Miguel Servet II contract by the Instituto de Salud Carlos III (number CPII18/00033).
- Published
- 2019
42. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice
- Author
-
CoRIS, Melchor Riera, J.L. Gómez-Sirvent, Nuria Espinosa, Joaquim Peraire, Julián Olalla, Natalia Chueca, Carlos Guerrero-Beltran, Silvia García-Bujalance, Mónica García-Álvarez, David Dalmau, Adrian Curran, David Vinuesa, Arkaitz Imaz, María J Pérez-Elías, Eva Poveda, Antonio Aguilera, José Ramón Blanco, Adolfo de Salazar, Paz Casas, Gemma Navarro, Irene Portilla, Félix Gutiérrez, Jesús Santos, Carlos Galera, Marta Álvarez, Carmen Rodríguez, José Miguel Molina, Federico García, Lucio García-Fraile, José Antonio Iribarren, and Beatriz Pierola
- Subjects
0301 basic medicine ,Microbiology (medical) ,Adult ,Male ,medicine.medical_specialty ,030106 microbiology ,Integrase inhibitor ,HIV Infections ,Drug resistance ,Emtricitabine ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Abacavir ,Internal medicine ,Drug Resistance, Viral ,medicine ,Prevalence ,Humans ,Pharmacology (medical) ,Public Health Surveillance ,030212 general & internal medicine ,HIV Integrase Inhibitors ,Aged ,Pharmacology ,Bictegravir ,business.industry ,Elvitegravir ,Middle Aged ,Raltegravir ,Infectious Diseases ,chemistry ,Spain ,Dolutegravir ,HIV-1 ,Female ,business ,medicine.drug - Abstract
Background: Integrase strand-transfer inhibitors (INSTIs) constitute at present one of the pillars of first-line ART. Objectives: To study the prevalence of and the trend in transmitted drug resistance (TDR) to INSTIs in ART-naive patients in Spain. Methods: During the period 2012-17, 1109 patients from CoRIS were analysed. The Stanford algorithm v8.7 was used to evaluate TDR and transmission of clinically relevant resistance. To describe individual mutations/polymorphisms, the most recent IAS list (for INSTIs) and the 2009 WHO list update (for the backbone NRTIs used in combination with INSTIs in first-line treatment) were used. Results: Clinically relevant resistance to the INSTI class was 0.2%: T66I, 0.1%, resistance to elvitegravir and intermediate resistance to raltegravir; and G163K, 0.1%, intermediate resistance to raltegravir and elvitegravir. No clinical resistance to dolutegravir or bictegravir was observed. The prevalence of INSTI TDR following the IAS-USA INSTI mutation list was 2.6%, with no trend towards changes in the prevalence throughout the study period. The overall prevalence of NRTI WHO mutations was 4.3%, whereas clinically relevant resistance to tenofovir, abacavir and emtricitabine/ lamivudine was 1.7%, 1.9% and 0.7%, respectively. Conclusions: Given the low prevalence of clinically relevant resistance to INSTIs and first-line NRTIs in Spain, it is very unlikely that a newly diagnosed patient will present with clinical resistance to a first-line INSTI-based regimen. These patients may not benefit from INSTI and NRTI baseline resistance testing.
- Published
- 2019
43. Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients
- Author
-
Dolores Merino, María Amparo Gómez-Vidal, Antonio Rivero, María Paniagua-García, Antonio Rivero-Juárez, Nuria Espinosa, J. Perez‐Stachowski, M. Castaño‐Carracedo, L. Muñoz‐Medina, Juan Macías, Elisa Fernández-Fuertes, Francisco Téllez, Antonio Collado, Jesús Santos, A. Zapata‐Lopez, Ministerio de Sanidad (España), Instituto de Salud Carlos III, and European Commission
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Longitudinal study ,genetic structures ,Hepatitis C virus ,Population ,HIV Infections ,medicine.disease_cause ,Antiviral Agents ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Longitudinal Studies ,Prospective Studies ,Barrier to treatment ,education ,Substance Abuse, Intravenous ,Aged ,Opioid substitution therapy ,Aged, 80 and over ,education.field_of_study ,business.industry ,Coinfection ,Health Policy ,virus diseases ,HIV ,Hepatitis C ,Odds ratio ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,030112 virology ,Confidence interval ,Drug Utilization ,Infectious Diseases ,Cohort ,Population study ,Female ,Direct‐acting antiviral treatment ,business ,People who inject drugs - Abstract
[Objectives]: Our objective was to identify patient factors associated with being untreated for hepatitis C virus (HCV) infection in HIV-coinfected patients., [Methods]: A prospective longitudinal study was carried out. HIV-infected patients with active chronic HCV infection included in the HERACLES cohort (NCT02511496) constituted the study population. The main study outcome was receipt of HCV direct-acting antiviral (DAA) treatment from 1 May 2015 to 1 May 2017. The population was divided into patients who were receiving HCV treatment during follow-up and those who were not., [Results]: Of the 15 556 HIV-infected patients in care, 3075 (19.7%) presented with chronic HCV infection and constituted the study population. At the end of the follow-up, 1957 patients initiated HCV therapy (63.6%). Age < 50 years, absence of or minimal liver fibrosis, being treatment-naïve, HCV genotype 3 infection, being in the category of people who inject drugs using opioid substitutive therapy (OST-PWID), and being in the category of recent PWID were identified as significant independent risk factors associated with low odds of DAA implementation. When a multivariate analysis was performed including only the PWID population, both OST-PWID [odds ratio (OR) 0.552; 95% confidence interval (CI) 0.409–0.746) and recent PWID (OR 0.019; 95% CI 0.004–0.087) were identified as independent factors associated with low odds of treatment implementation., [Conclusions]: We identified factors, which did not include prioritization of a DAA uptake strategy, that limited access to HCV therapy. The low treatment uptake in several populations seriously jeopardizes the elimination of HCV infection in the coming years., This work was supported by the Ministerio de Sanidad (RD12/0017/0012) integrated in the Plan Nacional de I+D+I, and cofinanced by the ISCIII‐Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER), the Fundación para la Investigación en Salud (FIS) del Instituto Carlos III (PI15/01017), and the Red de Investigación en SIDA de España ISCIII‐RETIC (grant number: RD16/0025/0034).
- Published
- 2018
44. Repeated Pulses of Methyl-Prednisolone in Adults Hospitalized With COVID-19 Pneumonia and Acute Respiratory Distress Syndrome: A Preliminary Before–After Study (CortiCOVID Study)
- Author
-
Maria Isabel Asensio-Cruz, Michelle Espinosa-Solano, Julia Praena-Segovia, Jose Molina Gil-Bermejo, Marta Ferrer-Galvan, José Manuel Lomas, María Paniagua-García, Elisa Cordero, Demetrio Gonzalez-Vergara, Manuel Garcia-Gutierrez, Macarena Borrero-Rodriguez, Alejandro Palomo, María Dolores Navarro-Amuedo, Manuela Aguilar-Guisado, Manuel Poyato, Cristina Roca-Oporto, Luis Jara-Palomares, Cesar Sotomayor, Candela Caballero-Eraso, and Nuria Espinosa
- Subjects
medicine.medical_specialty ,medicine.drug_class ,medicine.medical_treatment ,Tertiary referral hospital ,Dexamethasone ,Diseases of the respiratory system ,Internal medicine ,Neumonía ,medicine ,Intubation ,RC705-779 ,business.industry ,Standard treatment ,COVID-19 ,Pneumonia ,Odds ratio ,Dexametasona ,medicine.disease ,Confidence interval ,Severe acute respiratory syndrome ,Síndrome de distrés respiratorio agudo ,Methylprednisolone ,Corticosteroid ,Original Article ,business ,medicine.drug - Abstract
Introduction: The use of systemic corticosteroids in severely ill patients with coronavirus disease 2019 (COVID-19) is controversial. We aimed to evaluate the efficacy and safety of corticosteroid pulses in patients with COVID-19 pneumonia. Methods: A quasi-experimental study, before and after, was performed in a tertiary referral hospital, including admitted patients showing COVID-19-associated pneumonia. The standard treatment protocol included targeted COVID-19 antiviral therapy from 23rd March 2020, and additionally pulses of methylprednisolone from 30th March 2020. The primary outcome was a composite endpoint combining oro-tracheal intubation (OTI) and death within 7 days. Results: A total of 24 patients were included. Standard of care (SOC) (before intervention) was prescribed in 14 patients, while 10 received SOC plus pulses of methylprednisolone (after intervention). The median age of patients was 64.5 years and 83.3% of the patients were men. The primary composite endpoint occurred in 13 patients (92.9%) who received SOC vs. 2 patients (20%) that received pulses of methylprednisolone (odds ratio, 0.02; 95% confidence interval, 0.001 to 0.25; p = 0.019). Length of hospitalization in survivors was shorter in the corticosteroids group (median, 14.5 [8.5–21.8] days vs. 29 [23–31] days, p = 0.003). There were no differences in the development of infections between both groups. There were 3 deaths, none of them in the corticosteroids group. Conclusions: In patients with severe pneumonia due to COVID-19, the administration of methylprednisolone pulses was associated with a lower rate of OTI and/or death and a shorter hospitalization episode. Resumen: Introducción: El uso de corticosteroides sistémicos en pacientes gravemente enfermos por enfermedad coronavírica de 2019 (covid-19) es controvertido. Nuestro objetivo fue evaluar la eficacia y la seguridad de los pulsos de corticoesteroides en los pacientes con neumonía por covid-19. Métodos: Se realizó un ensayo cuasiexperimental, tipo antes y después, en un hospital terciario de referencia que incluyó a pacientes ingresados por neumonía asociada a covid-19. El protocolo de tratamiento estándar incluía un tratamiento antiviral dirigido contra el virus de la covid-19 desde el 23 de marzo de 2020 y añadió pulsos de metilprednisolona desde el 30 de marzo de 2020. El resultado primario fue un criterio combinado compuesto por la intubación orotraqueal y el fallecimiento durante los siguientes siete días. Resultados: Se incluyó un total de 24 pacientes. El protocolo de tratamiento (antes de la intervención) se prescribió en 14 pacientes, mientras que 10 recibieron el protocolo de tratamiento además de los pulsos de metilprednisolona (después de la intervención). La edad media de los pacientes fue de 64,5 años y el 83,3% de los pacientes eran hombres. El resultado combinado primario tuvo lugar en 13 pacientes (92,9%) que recibieron el protocolo de tratamiento frente a 2 pacientes (20%) que recibieron los pulsos de metilprednisolona (odds ratio = 0,02; intervalo de confianza del 95% = 0,001-0,25; p = 0,019). La duración de la hospitalización en los supervivientes fue más corta en el grupo que recibió corticoesteroides (media = 14,5 [8,5-21,8] días frente a 29 [23-31] días, p = 0,003). No hubo diferencias en el desarrollo de infecciones entre ambos grupos. Hubo tres fallecimientos, ninguno de ellos en el grupo que recibió corticoesteroides. Conclusiones: En los pacientes con neumonía grave por covid-19, la administración de pulsos de metilprednisolona se asoció a unas tasas menores de intubación orotraqueal y/o muerte y a episodios de hospitalización más cortos.
- Published
- 2021
45. Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir-vs. efavirenz-based antiretroviral therapy
- Author
-
Consuelo Viladés, Nuria Espinosa, VERONICA ALBA ELVIRA, Jose-Ramon Blanco, Miriam Estebanez, Sergio Veloso Esteban, INMA JARRIN, Andrés Navarro Ruiz, Enrique Bernal Morell, Paloma Gijon, Mar Masiá, Livia Giner, Francesc Vidal, DAVID DALMAU, Montserrat Vargas Laguna, JUAN JOSE SIRVENT, Jesús Miguel López Dupla, Vicente Estrada, Maria Luisa Montes, Vicente Boix, Sergio Padilla, Esperanza Merino de Lucas, Dulcenombre Gomez-Garre, Susana Monge, Luis Fernando Lopez.Cortes, Jesus Mingorance, Rafael Rubio García, Félix Gutiérrez, Juan Berenguer, Cristina Gonzalez, Víctor Hontañón Antoñana, Jose Luis Casado, Jose Arribas, Mª Jesus Perez Elias, and Joaquín Portilla
- Subjects
Adult ,Cyclopropanes ,Male ,medicine.medical_specialty ,Efavirenz ,Bilirubin ,Atazanavir Sulfate ,HIV Infections ,030204 cardiovascular system & hematology ,Gastroenterology ,Plasma ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Prospective Studies ,030212 general & internal medicine ,Prospective cohort study ,Peroxidase ,business.industry ,Health Policy ,Confidence interval ,Benzoxazines ,Atazanavir ,Lipoproteins, LDL ,Oxidative Stress ,Phospholipases A2 ,Regimen ,Infectious Diseases ,Anti-Retroviral Agents ,chemistry ,Alkynes ,Immunology ,Female ,Ritonavir ,business ,Biomarkers ,medicine.drug - Abstract
Objectives Chronic oxidative stress (OS) may play a role in cardiovascular disease in HIV-infected patients, and increased bilirubin levels may have a beneficial role in counteracting OS. Atazanavir (ATV) inhibits UDP-glucuronosyl-transferase 1A1 (UGT1A1), thus increasing unconjugated bilirubin levels. We aimed to compare changes in OS markers in patients on ATV/ritonavir (ATV/r)- vs. efavirenz (EFV)-based first-line antiretroviral therapy (ART). Methods A multicentre, prospective cohort study of HIV-infected patients who started first-line ART with either ATV/r or EFV was conducted. Lipoprotein-associated phospholipase A2 (Lp-PLA2), myeloperoxidase (MPO) and oxidized low-density lipoprotein (oxLDL) were measured for 145 patients in samples obtained at baseline and after at least 9 months of ART during which the initial regimen was maintained and the patient was virologically suppressed. The change in OS markers was modelled using multiple linear regressions adjusting for baseline values and confounders. Results After adjustment for baseline variables, patients on ATV/r had a significantly greater decrease in Lp-PLA2 [estimated difference -16.3; 95% confidence interval (CI) -31.4, -1.25; P = 0.03] and a significantly smaller increase in OxLDL (estimated difference -21.8; 95% CI -38.0, -5.6; P < 0.01) relative to those on EFV, whereas changes in MPO were not significantly different (estimated difference 1.2; 95% CI -14.3, 16.7; P = 0.88). Adjusted changes in bilirubin were significantly greater for the ATV/r group than for the EFV group (estimated difference 1.33 mg/dL; 95% CI 1.03, 1.52 mg/dL; P < 0.01). Changes in bilirubin and changes in OS markers were significantly correlated. Conclusions When compared with EFV, ATV/r-based therapy was associated with lower levels of oxidative stress biomarkers, which was in part attributable to increased bilirubin levels.
- Published
- 2016
46. Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis
- Author
-
Dolores Merino, Ana María Martínez-Sapiña, María Jesús Vivancos, Francisco Téllez, Antonio Rivero-Juárez, Lize Cuypers, Natalia Chueca, Teresa Aldámiz-Echevarría, Nuria Espinosa, Javier Salmerón, Ana Belén Pérez, Juan Carlos Alados, Anne-Mieke Vandamme, Juan A. Pineda, Federico García, and Víctor Hontañón
- Subjects
0301 basic medicine ,Male ,RNA viruses ,Molecular biology ,lcsh:Medicine ,Gene Sequencing ,HIV Infections ,Hepacivirus ,medicine.disease_cause ,Database and Informatics Methods ,Sequencing techniques ,Immunodeficiency Viruses ,Recurrence ,Genotype ,DNA sequencing ,lcsh:Science ,Phylogeny ,Pathology and laboratory medicine ,Data Management ,Multidisciplinary ,Transmission (medicine) ,Coinfection ,Hepatitis C virus ,Phylogenetic Analysis ,Hepatitis C ,Medical microbiology ,Phylogenetics ,Viruses ,Infectious diseases ,Pathogens ,Sequence Analysis ,Research Article ,medicine.medical_specialty ,Computer and Information Sciences ,Bioinformatics ,Genome, Viral ,Viral diseases ,Research and Analysis Methods ,Antiviral Agents ,Microbiology ,Virus ,03 medical and health sciences ,Pharmacotherapy ,Internal medicine ,Molecular genetics ,Retroviruses ,medicine ,Genetics ,Humans ,Evolutionary Systematics ,Homosexuality, Male ,Taxonomy ,Hepatitis ,Medicine and health sciences ,Evolutionary Biology ,Flaviviruses ,business.industry ,lcsh:R ,Lentivirus ,Organisms ,Viral pathogens ,Biology and Life Sciences ,HIV ,Human Genetics ,Hepatitis C, Chronic ,medicine.disease ,Hepatitis viruses ,Microbial pathogens ,030104 developmental biology ,Molecular biology techniques ,lcsh:Q ,business ,Sequence Alignment - Abstract
Despite high response rates associated to hepatitis C virus (HCV) treatment, no protective immunity is acquired, allowing for reinfection and continued infectiousness. Distinguishing between relapse and reinfection is crucial for patient counselling and to choose the most appropriate retreatment. Here, refined phylogenetic analysis using multiple genes served to assess genotype and reinfection for 53 patients for whom the virus was sampled before start of therapy and at time of sustained virological response evaluation at week 12. At baseline, genotypes were determined as HCV1a (41.5%), HCV1b (24.5%), HCV4 (18.9%) and HCV3a (15.1%), while six cases revealed to be discordantly assigned by phylogeny and commercial assays. Overall, 60.4% was co-infected with HIV. The large majority was classified as people who inject drugs (78.6%), often co-infected with HIV. Transmission was sexual in seven cases, of which five in HIV-positive men-who-have-sex-with-men. Overall, relapse was defined for 44 patients, while no conclusion was drawn for four patients. Five patients were reinfected with a different HCV strain, of which three with a different genotype, showing that phylogeny is needed not only to determine the genotype, but also to distinguish between relapse and intra-subtype reinfection. Of note, phylogenies are more reliable when longer fragments of the viral genome are being sequenced. ispartof: PLOS ONE vol:13 issue:7 ispartof: location:United States status: published
- Published
- 2018
47. Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations
- Author
-
Tamara Fernandez-Magdaleno, Luis F. López-Cortés, Maria Trujillo-Rodriguez, Nuria Espinosa, Alicia Gutierrez-Valencia, Pompeyo Viciana, [Gutierrez-Valencia, Alicia] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla,Enfermedades Infecciosas Micr, Lab 213,Ave Manuel Siurot S-N, Seville 41013, Spain, [Trujillo-Rodriguez, Maria] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla,Enfermedades Infecciosas Micr, Lab 213,Ave Manuel Siurot S-N, Seville 41013, Spain, [Fernandez-Magdaleno, Tamara] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla,Enfermedades Infecciosas Micr, Lab 213,Ave Manuel Siurot S-N, Seville 41013, Spain, [Espinosa, Nuria] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla,Enfermedades Infecciosas Micr, Lab 213,Ave Manuel Siurot S-N, Seville 41013, Spain, [Viciana, Pompeyo] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla,Enfermedades Infecciosas Micr, Lab 213,Ave Manuel Siurot S-N, Seville 41013, Spain, and [Lopez-Cortes, Luis F.] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla,Enfermedades Infecciosas Micr, Lab 213,Ave Manuel Siurot S-N, Seville 41013, Spain
- Subjects
0301 basic medicine ,Male ,Darunavir+Ritonavir ,HIV Infections ,Gastroenterology ,0302 clinical medicine ,Short Reports ,Open-label ,030212 general & internal medicine ,Prospective Studies ,pharmacokinetic ,Lopinavir/ritonavir monotherapy ,Ctrough ,Darunavir ,Cobicistat ,Hiv-1-infected patients ,Middle Aged ,Viral Load ,ritonavir ,Infectious Diseases ,monotherapy ,Cohort ,Reverse Transcriptase Inhibitors ,Drug Therapy, Combination ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,Protease-inhibitor monotherapy ,Efficacy ,Anti-HIV Agents ,Darunavir/Cobicistat ,030106 microbiology ,Short Report ,03 medical and health sciences ,Pharmacokinetics ,Internal medicine ,medicine ,Humans ,Trough Concentration ,Triple therapy ,C-trough ,Ritonavir ,Lopinavir-ritonavir monotherapy ,business.industry ,Public Health, Environmental and Occupational Health ,cobicistat ,Viral suppression ,Monet trial ,Maintenance therapy ,business - Abstract
Introduction When darunavir (DRV) 800 mg is boosted with 150 mg cobicistat (DRV cobi), DRV trough concentration (Ctrough) is about 30% lower as compared to 100 mg ritonavir (DRV rtv). DRV cobi shows similar virological efficacy as DRV rtv when combined with two nucleos(t)ide analogue reverse‐transcriptase inhibitors, but it is unknown whether a lower DRV Ctrough would undermine the effectiveness of DRV cobi when given as monotherapy (mtDRV cobi). Methods Prospective observational study on virologically suppressed HIV‐infected subjects who switched to mtDRV cobi. Virological failure was defined as two consecutive HIV‐RNA >200 copies/mL. Efficacy was evaluated by intention‐to‐treat (ITT) and on‐treatment (OT) analyses, and compared with data from a previous cohort of subjects on mtDRV rtv conducted at our centre. Plasma DRV Ctrough was measured using LC–MS/MS. Results A total of 234 subjects were enrolled. At week 96, the efficacy rates were 67.8% (CI 95, 61.8 to 73.7) by ITT and 86.9% (CI 95, 78.0 to 87.7) by OT analyses. The corresponding rates in our historical DRV rtv controls were 67.6% (CI 95, 60.0 to 75.2) and 83.6% (CI 95: 77.2 to 90.0). A total of 135 DRV determinations were performed in 83 subjects throughout the follow‐up period, with a median plasma DRV Ctrough of 1305 ng/mL (range, 150 to 5895) compared with 1710 ng/mL (range, 200 to 3838) in subjects on monotherapy with DRV rtv (p = 0.05). Conclusions DRV Ctrough was lower in HIV‐infected subjects receiving DRV cobi than with DRV rtv. However, this did not appear to influence the efficacy of DRV cobi, when administered as monotherapy.
- Published
- 2018
48. Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients
- Author
-
Tamara Fernandez-Magdaleno, Alicia Gutierrez-Valencia, Omar J. BenMarzouk-Hidalgo, Pompeyo Viciana, Silvia Llaves, Luis F. López-Cortés, Nuria Espinosa, and Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
- Subjects
Adult ,Male ,0301 basic medicine ,Microbiology (medical) ,Anti-HIV Agents ,HIV Infections ,Quinolones ,Pharmacology ,Emtricitabine ,Young Adult ,03 medical and health sciences ,Pharmacokinetics ,medicine ,Humans ,Hiv infected patients ,Drug Interactions ,Pharmacology (medical) ,Darunavir ,Aged ,Aged, 80 and over ,Elvitegravir ,business.industry ,Cobicistat ,Middle Aged ,030112 virology ,Drug Combinations ,Regimen ,Infectious Diseases ,HIV-1 ,Population study ,Female ,business ,medicine.drug - Abstract
[Objectives] To evaluate if there are significant drug–drug interactions between cobicistat-boosted elvitegravir and 800 mg darunavir once daily taken simultaneously, as has been suggested previously., [Methods] The study population consisted of three groups of unselected volunteers taking a regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate (150, 150, 200 and 300 mg, respectively) co-formulated in a single tablet plus 800 mg darunavir (group A); only co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate (group B); and cobicistat-boosted darunavir (800 mg darunavir + 150 mg cobicistat) plus two nucleos(t)ide analogues (group C). Elvitegravir, cobicistat and darunavir concentrations at the end of the dosing interval (C24) were quantified using a validated LC with tandem MS method., [Results] A total of 170 samples were obtained from 24, 32 and 32 patients in groups A, B and C, respectively. In group A, the elvitegravir C24 were similar to those in group B (233.67 versus 250.39 ng/mL) (P = 0.406) and the darunavir C24 were similar to those in group C (1293.54 versus 1319.34 ng/mL) (P = 0.908). The cobicistat C24 were comparable in groups A and B (20.2 versus 20.9 ng/mL) and slightly higher in group C (27.7 ng/mL) (P = 0.059)., [Conclusions] The results provide evidence of similar elvitegravir and darunavir C24 concentrations when these drugs are co-administered as co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate plus 800 mg darunavir or dosed separately., This work was supported by Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
- Published
- 2017
49. Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients
- Author
-
T. Martin, Jorge Vergas, Victoria Moreno, Juan Flores, Luis Force, J. C. Lopez Bernaldo de Quiros, Jordi Curto, Jhon Rojas, Antonio Ocampo, Bonaventura Clotet, Angela Camacho, José Antonio Iribarren, Arkaitz Imaz, J.L. Gómez-Sirvent, Nerea Rozas, Victor Asensi, Eulalia Valencia, Nuria Espinosa, Pablo Bachiller, Hernando Knobel, José Ramón Blanco, Pompeyo Viciana, Manuel Castaño, Iris A Perez, Daniel Podzamczer, and Universitat de Vic. Càtedra de la Sida i Malalties Relacionades
- Subjects
Adult ,Male ,Microbiology (medical) ,medicine.medical_specialty ,Anti-HIV Agents ,HIV Infections ,Pharmacology ,Cohort Studies ,Young Adult ,Abacavir ,Antiretroviral Therapy, Highly Active ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Adverse effect ,Darunavir ,Aged ,Retrospective Studies ,Aged, 80 and over ,Sulfonamides ,Ritonavir ,business.industry ,virus diseases ,Lamivudine ,Abacavir/Lamivudine ,Sida -- Tractament ,Middle Aged ,Viral Load ,Dideoxynucleosides ,Discontinuation ,Drug Combinations ,Regimen ,Treatment Outcome ,Infectious Diseases ,Spain ,HIV-1 ,Female ,business ,medicine.drug - Abstract
Objectives: To present clinical experience with a regimen including abacavir/lamivudine+darunavir/ritonavir in a cohort of HIV-1-infected patients. Methods: A retrospective, multicentre cohort study, including all consecutive adult HIV-1-infected patients who started abacavir/lamivudine+darunavir/ritonavir from April 2008 to December 2010 and had at least one followup visit. The primary endpoint was HIV-1 viral load (VL) ,40 copies/mL at week 48. Results: One hundred and eighty-three patients (42 naive and 141 experienced) from 19 hospitals in Spain were studied. The median follow-up was 26.7 (0.5–58.6) months, 79.8% were men, the median age was 47.1 (21.4– 80.5) years, 26.2% had AIDS and 38.8% were positive for hepatitis C virus. At baseline, the median CD4 count was 246 cells/mm3 in naive patients and 393 cells/mm3 in experienced patients and the median VL was 4.80 and ,1.59 log copies/mL, respectively. Atweek 48, 81.8% of naive patients and 84.2% of experienced patients receiving the regimen reached a VL ,40 copies/mL, whereas at 96 weeks this occurred in 90.5% and 92.8%, respectively. CD4 cell count increases at 48 and 96 weeks were +176.5 and +283.5 cells/mm3 in naive patients and +74.9 and +93 cells/mm3 in experienced patients, respectively. Overall, 86 (47%) patients discontinued the study regimen, in many cases possibly related to non-medical reasons, such as drug switches to reduce cost or changes in address due to economic constraints. Three patients died of causes unrelated to therapy and 19 (10.4%) discontinued the regimen due to adverse events. Conclusions: In our cohort, abacavir/lamivudine+darunavir/ritonavir was safe, well tolerated and achieved high rates of virological suppression. In a proportion of patients, discontinuation of this effective regimen was possibly due to non-medical reasons.
- Published
- 2014
50. Viral Kinetics in Semen With Different Antiretroviral Families in Treatment-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Trial
- Author
-
Nuria Espinosa, Alicia Gutierrez-Valencia, Maria Trujillo-Rodriguez, Inmaculada Rivas-Jeremías, Pompeyo Viciana, Omar J. BenMarzouk-Hidalgo, Luis F. López-Cortés, Tamara Fernandez-Magdaleno, [Gutierrez-Valencia, Alicia] Univ Seville, Enfermedades Infecciosas Microbiol & Med Prevent, Inst Biomed Sevilla, Hosp Univ Virgen Rocio,CSIC, Seville, Spain, [Benmarzouk-Hidalgo, Omar J.] Univ Seville, Enfermedades Infecciosas Microbiol & Med Prevent, Inst Biomed Sevilla, Hosp Univ Virgen Rocio,CSIC, Seville, Spain, [Rivas-Jeremias, Inmaculada] Univ Seville, Enfermedades Infecciosas Microbiol & Med Prevent, Inst Biomed Sevilla, Hosp Univ Virgen Rocio,CSIC, Seville, Spain, [Espinosa, Nuria] Univ Seville, Enfermedades Infecciosas Microbiol & Med Prevent, Inst Biomed Sevilla, Hosp Univ Virgen Rocio,CSIC, Seville, Spain, [Trujillo-Rodriguez, Maria] Univ Seville, Enfermedades Infecciosas Microbiol & Med Prevent, Inst Biomed Sevilla, Hosp Univ Virgen Rocio,CSIC, Seville, Spain, [Fernandez-Magdaleno, Tamara] Univ Seville, Enfermedades Infecciosas Microbiol & Med Prevent, Inst Biomed Sevilla, Hosp Univ Virgen Rocio,CSIC, Seville, Spain, [Viciana, Pompeyo] Univ Seville, Enfermedades Infecciosas Microbiol & Med Prevent, Inst Biomed Sevilla, Hosp Univ Virgen Rocio,CSIC, Seville, Spain, [Lopez-Cortes, Luis F.] Univ Seville, Enfermedades Infecciosas Microbiol & Med Prevent, Inst Biomed Sevilla, Hosp Univ Virgen Rocio,CSIC, Seville, Spain, and Gilead Science
- Subjects
0301 basic medicine ,Microbiology (medical) ,antiretroviral treatment ,Adult ,Male ,030106 microbiology ,Co-formulated elvitegravir ,HIV Infections ,Emtricitabine ,Hiv-1 rna ,03 medical and health sciences ,chemistry.chemical_compound ,Young Adult ,Wild-type ,Semen ,Blood plasma ,medicine ,Humans ,Darunavir ,Compartments ,business.industry ,Elvitegravir ,Cobicistat ,Rilpivirine ,Double-blind ,Initial treatment ,semen ,Middle Aged ,Viral Load ,Virology ,Kinetics ,Infectious Diseases ,Blood ,chemistry ,male genital tract ,Anti-Retroviral Agents ,Dolutegravir ,HIV-1 ,RNA, Viral ,Ritonavir ,business ,Viral load ,medicine.drug - Abstract
Background There are several regimens for starting antiretroviral treatment, but it remains unknown whether either of them is more advantageous regarding the time course and magnitude of human immunodeficiency virus (HIV) RNA decay in semen. Objective To evaluate the differential effect of different antiretroviral drug families on viral kinetics in seminal plasma (SP) of treatment-naive HIV-infected patients. Methods Phase II, randomized, open-label study in which participants were randomized 1:1:1 to receive tenofovir-disoproxil fumarate (DF) plus emtricitabine, and either cobicistat-boosted elvitegravir (EVGcobi), rilpivirine (RPV), or ritonavir-boosted darunavir (DRVrtv). The primary endpoint was the proportion of participants with undetectable HIV-RNA in SP at week 12. HIV type 1 (HIV-1) RNA was measured in paired SP and blood plasma (BP) at baseline and after 1, 2, 4, 6, 8, 12, 18, and 24 weeks. Elvitegravir (EVG), RPV, and darunavir (DRV) concentrations were quantified by the liquid chromatography-tandem mass spectrometry method. Results In SP, the HIV-RNA decay rate with RPV was as fast as with EVGcobi; by week 12, all participants in the RPV and the EVGcobi groups reached an undetectable viral load but only 58.3% in the DRVrtv arm (P = .003). The highest SP/BP drug concentration ratio was for EVG (0.43), followed-up by RPV (0.19), and DRV (0.10). For both EVG and RPV, the SP concentrations exceeded >2-fold the protein binding-adjusted EC90 for wild-type HIV-1; for DRV, only 33.7% of the SP showed concentrations above the protein binding-adjusted EC90. Conclusions In SP, both RPV and EVGcobi, associated to tenofovir-DF and emtricitabine, behave similarly and achieve an undetectable viral load much faster than DRVrtv. Registration European Medical Agency (No. EudraCT: 2014-001348-39).
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.